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2. Summary (English) 
Attempts to improve formulation of topical products are a continuing process i.e. to increase cosmetic 
performance, enhance effects and protect ingredients from degradation. The development of micro and 
nano-vesicular systems has lead to marketing of topical drugs and cosmetics using these technologies. 
Several papers have reported improved clinical efficacy by encapsulating pharmaceuticals in vesicular 
systems. Some vesicular systems may improve transdermal delivery of compounds compared to 
conventional vehicles. Few case reports have suggested that microvesicle formulations may affect 
allergenicity of topical products. 
The aim of this thesis is to investigate the effect on the sensitizing and elicitation capacity of chemical 
allergens encapsulated in vesicular systems.  
The first part examined how the encapsulation of isoeugenol, dinitro-chloro-benzene, and potassium 
dichromate in liposomes, ethosomes and polycaprolactone affects the sensitizing properties using the 
OECD and FDA approved skin sensitisation test method in mice: the Local Lymph Node Assay. 
Ethanolic liposome (Ethosome) formulation of lipophilic allergens increased the sensitising capacity 
and polycaprolactone protected against sensitisation compared to conventional vehicles.  The 
formulation of the hydrophilic allergen, potassium dichromate, in all three drug delivery systems did 
not affect the sensitisation capacity. Further, the effect of vesicle size was studied and conflicting 
results were found. 
The second part examined whether encapsulation of allergens in ethosomes affects the patch test 
reactivity and outcome of the Repeated Open Application Test (ROAT) compared to test with 
ethanol:water formulations. Pre-sensitized volunteer individuals were patch tested with a dilution 
series of isoeugenol and methyldibromoglutaronitrile formulated in ethosomes and ethanol:water. Both 
contact allergens encapsulated in ethosomes showed significantly enhanced patch test reactions 
compared to the allergen preparation in ethanol:water without ethosomes. No significant difference in 
the median lag time was recorded between preparations in the repeated open application test.  
 The third part examined the percutaneous absorption in vitro of dinitro-chloro-benzene and 
isoeugenol formulated in ethosomes and ethanol:water using Franz cells and human cadaver skin. We 
found no significant relationship between percutaneous skin absorption /penetration of the allergens 
and the sensitising properties of the test formulations.  
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Conclusion 
Encapsulation of lipophilic contact allergens in lipid vesicles and nanospheres may affect the 
sensitising and elicitation capacity of the encapsulated allergen. Encapsulation of the hydrophilic 
allergen potassium dichromate did not alter the sensitizing capacity in the Local Lymph Node Assay. 
We did not find a correlation between the percutaneous skin absorption/penetration pattern and the 
sensitising capacity. The clinical implications of these results are so far uncertain. However, the 
cosmetic industry should consider the effect of encapsulation on a case by case basis because certain 
ingredients may become more allergenic when encapsulated.  Dermatologists investigating patients 
with allergic reactions to consumer products using encapsulation technology should consider the risk 
of false negative results, if testing with ingredients in conventional patch test vehicles. Testing with 
encapsulated ingredients should be performed when possible.   
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3. Resumé (dansk) 
Kosmetik og lægemiddelindustrien udvikler hele tiden nye formuleringstyper til lokal anvendelse med 
det formål at forbedre effekten, beskytte de aktive stoffer mod nedbrydning og ikke mindst øge den 
kosmetiske oplevelse. Udviklingen af mikro og nanovesikler i 1960’érne gjorde det muligt at 
indkapsle aktive ingredienser i produkterne for at beskytte dem mod nedbrydning, og for at øge 
penetrationen i huden med henblik på at øge effekten. Flere hudprodukter, der anvender denne 
teknologi, er markedsført. Enkelte kasuistiske meddelelser har antydet, at disse nye 
formuleringsmetoder kan øge det indkapslede stofs allergifremkaldende egenskaber.  
Formålet med denne ph.d afhandling er at undersøge, hvorvidt indkapsling af kendte allergener i 
sådanne vesikelformuleringer øger stoffernes sensibiliserings- og provokations egenskaber for 
udvikling af kontaktallergi.  
Første del undersøger, hvordan indkapslingen af allergenerne isoeugenol, dinitro-chloro-benzen og 
kaliumdikromat indkapslet i liposomer, ethosomer og polycaprolacton påvirker sensibiliseringsfasen i 
en musemodel. Sensibiliserings testen ”The Local Lymph Node Assay”, der er valideret og godkendt 
af OECD og FDA, anvendes. Forsøgene viser, at ethosomer øger de lipofile allergeners (isoeugenol og 
dinitro-chloro-benzene) sensibiliseringsegenskaber, hvorimod polycaprolacton beskytter mod 
sensibilisering. Indkapslingen af kaliumdikromat i alle tre vesikelsystemer har ingen effekt på 
sensibiliseringen. Hvorvidt størrelsen af vesiklerne spiller en rolle er uklart, da der fremkommer 
modsat rettede resultater. 
Anden del af afhandlingen viser resultaterne fra kliniske provokationsforsøg på præ-sensibiliserede, 
frivillige forsøgspersoner, der tidligere har fået påvist en positiv lappeprøve (epikutantest) over for 
isoeugenol eller methyldibromoglutaronitril.  Epikutantest med allergenerne fremkalder en signifikant 
kraftigere eksem reaktion for ethosomformuleringens vedkommende sammenlignet med 
formuleringen uden brug af ethosomer. En ”repeated open application test” viser ingen signifikant 
forskel mellem de to formuleringstyper.   
Tredie del forsøger at påvise en sammenhæng mellem den påviste øgede sensibilieringsgrad for 
ethosomformuleringerne og den perkutane absorption/penetration. Disse studier er udført på kadaver 
hud med brug af Franz celler. Der kan ikke påvises en sammenhæng mellem penetrationsdybden eller 
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den perkutane absorption og sensibiliseringsgraden med allergenerne formuleret med og uden 
ethosomer. Tværtimod ser det ud til, at allergenets penetrationsdybde ikke spiller nogen rolle for 
sensibiliseringspotentialet. 
Konklusion 
Formuleringen af lipofile kontaktallergener i nogle vesikelsystemer kan øge allergenets 
sensibiliserende og provokerende egenskaber. Den kliniske betydning er ikke klarlagt, men kosmetik- 
og lægemiddelindustrien bør overveje risikoen for udvikling af kontaktallergi, når de udvikler nye 
produkter, der gør brug af denne teknologi. Når hudlæger undersøger for en kontaktallergi forårsaget 
af et forbrugerprodukt, der anvender denne indkapslingsteknologi, skal risikoen for et falsk negativt 
resultat nøje overvejes, hvis der udelukkende er testet med konventionelle vehikler. Hvis det er muligt, 
bør man teste med det anvendte vesikelsystem som vehikel.  
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4. Introduction 
4.1. Contact allergy 
Allergic contact dermatitis is the clinical manifestation of contact allergy and can occur upon re-
exposure to the allergen at the site of skin contact and results in eczema. Allergic contact dermatitis is 
a delayed type IV reaction and is responsible for only a minor part of the spectrum of contact 
dermatitis. The most common type of contact dermatitis is irritant contact dermatitis, a local 
inflammatory response in the skin that requires no prior sensitization. Irritant contact dermatitis results 
from direct chemical and physical irritant exposures to the skin - often due to wet work and 
detergents(1). Irritant and allergic contact dermatitis may result in sick leave and even change of job if 
the dermatitis is work related.  
10% of the general population in Denmark were in 2006 sensitized to one or more chemicals from the 
environment (2). Cosmetic ingredients such as perfumes and preservatives often cause sensitization 
and allergic contact dermatitis and the labelling requirements given in the European Union Cosmetics 
Directive is of great help in tracing the causative allergenic ingredients (3). The most common causes 
of contact allergy are nickel followed by fragrances and preservatives (4).  
Allergic contact dermatitis involves two phases. The induction (sensitization) phase and the effector 
(elicitation) phase. Key factors in developing contact allergy are the physicochemical properties of the 
allergen that allows it to penetrate stratum corneum into epidermis and its ability to react with proteins 
in epidermis making a hapten-protein complex capable of eliciting an immune response through 
contact with the Langerhans cells (5). The amount of allergen applied per skin surface area, the 
frequency of application and the vehicle used are other important factors in developing contact allergy 
(6-8). The mechanisms of both phases of contact allergy have been studied for more than seven 
decades and even though many factors are elucidated, others are not well understood,  like how the 
effect of carrier vehicles for allergens affects skin absorption of the allergen and how this is related to 
the sensitising properties.  
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4.2. Sensitization 
Skin sensitization is a T-cell mediated immune response. A hapten is a small molecule (below 1000 
dalton) which reacts with proteins in the epidermis. During the sensitization process  the hapten binds 
to skin components and the hapten-protein conjugate functions as an antigen, which is processed by 
the Langerhans cells (antigen presenting cells) and presented to and recognized by T-cells (Figure 1). 
The Langerhans cells migrate to the local lymph nodes where they present the antigen to the T-cells. If 
the hapten-protein complexes are formed in the Langerhans cell, which is the case for some lipophilic 
haptens, they will be presented on MHC class I molecules and presented to CD8+ T cells. If the 
hapten-protein complexes are formed outside the Langerhans cell, they will be presented on MHC 
class II molecules to CD4+ T cells. The exact role of these two routes is not elucidated in detail. T-
 
 
Figure 1. 
Schematic presentation of the sensitization and elicitation phases of allergic contact allergy.  (1) Hapten penetrates the 
epidermis and bind to a protein whereupon (2) the complex is being internalized by the Langerhans cell.  (3) The 
Langerhans cell is activated and begins to migrate to the local lymph nodes where the hapten-protein complex is presented 
to naïve T-cells either on MHC-I or MHC-II molecules on the surface of the Langerhans cell (4).  (5) proliferation of 
hapten specific T-cells are formed and (6) leave the lymph nodes into the circulation.  Upon re-exposure to the hapten (7) a 
release of cytokines and chemokines are released and attract the hapten specific T-cells from the circulation and other non 
specific inflammatory cells to the area (8).  (9) An inflammatory process begins resulting in dermatitis within 1-2 days 
depending on the dose and potency of the hapten.  (illustration from Karlberg et al. (9)) 
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cells with receptors able to recognize the hapten-protein complex proliferates and circulate 
systemically throughout the body. These events constitute the induction, afferent or sensitization phase 
(10;11). 
Hundreds of chemicals are today registered as contact sensitizers and new ones keep coming up as 
new chemicals are used in industry and in topical products. Predictive sensitization assays in animal 
and man are developed to detect sensitizers with the purpose to protect workers and consumers by 
regulating the presence of significant contact allergens in products on the market. Attempts are made 
to replace animal assays by in-vitro assays to reduce the need for animal experiments, since a ban 
within the European Union (EU) of allergy testing  of cosmetics and toiletry ingredients  is planned to 
be implemented in 2013 (10).  Data on existing in-vitro assays show good correlation to animal 
predictive sensitization test methods, but only for moderate and strong sensitizers. These test methods 
are not yet approved to replace animal experiments, but they can be used to screen chemicals of 
interest before using animal test methods (9). 
4.2.1. The Local Lymph Node Assay (LLNA) 
Today the mouse Local Lymph Node Assay is the predictive sensitization test of choice (Figure 2). It 
has almost replaced the use of guinea pig test methods, with the guinea pig maximization test and the 
Buehler test as the most widely used. The Local Lymph Node Assay is less stressful for the animals, 
gives an objective outcome and reduces the number of animals compared to the guinea pig tests. The 
Local Lymph Node Assay only requires 4 groups of 4 mice to run a sensitization experiment 
compared to 15 animals in each group of guinea pigs. The Local Lymph Node Assay has a 
quantitative outcome (dose-response) allowing discriminating between four degrees of sensitization 
compared to the semi-quantitative guinea pig methods only dividing the allergens in weak or strong 
sensitizers. The Local Lymph Node Assay is internationally validated  and results correlate  well with 
human data, even though exceptions exist i.e. false positive results with some skin irritants i.e. sodium 
lauryl sulfate (11;12) and false negative results with some metals  in certain vehicles (13). The vehicle 
is thus of major importance and may also affect the sensitizing capacity (14). It is important that the 
test chemical is soluble in the vehicle chosen and that the test chemical suspected being a sensitizer is 
in the same oxidative state as when the chemical is in contact with the skin. Some fragrances like 
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linalyl acetate listed on the product label of toiletries may oxidize when in contact with air and become 
more potent sensitizers. (15). 
 
4.3. Elicitation 
After proliferation and dissemination of specific T-cells the sensitized individual is capable of 
developing an allergic contact dermatitis following renewed skin contact with the hapten or a chemical 
cross reactive with the primary sensitizer. The hapten-protein complex is again presented to the 
circulating T-cells by the Langerhans cells. The activated T-cells trigger a cascade of biochemical and 
cellular processes leading to inflammation of the skin at the site of contact. A much lower 
concentration of allergens is needed in this process due to the higher amount of circulating memory T-
cells compared to naïve T-cells required in the sensitizing phase. These events constitute as the 
Figure 2.  
The protocol of The Local Lymph Node Assay. At days 1, 2 and 3 25µl of test substance is applied on the dorsum of both 
ears. At day 6 the mice are injected with 250 µl phosphate buffered saline (PBS) containing 20 µCi [methyl]-3H-thymidine 
in the tail vein. Five hours later the mice are killed and the auricular lymph nodes removed and a single cell suspension is 
made. The lymph nodes of each group of animals are not pooled. The single cell suspension is washed with PBS and 
centrifuged twice.  The DNA is precipitated with 5% trichloro acetic acid (TCA) overnight and then resuspended in 1ml 
TCA and transferred to scintillation vials and [methyl]-3H-thymidine is measured by β-scintillation.   
 
Days 1,2 and 3 : 
Open application of 
chemicals
Day 6 – Tail vein
injection of         
3H-thymidine
Single cell
suspension
Determine 3H-
thymidine 
incorporation
by liquid
scintillaion
counting
After 5 hours the 
local lymph nodes 
are removed
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elicitation, effector or efferent phase. Contact allergy is thus regarded as a life long specific 
immunologic hypersensitivity (11). 
4.4. Test methods for diagnosing contact allergy 
4.4.1. Diagnostic patch testing 
Patch testing (epicutaneous testing) is the standard method for diagnosing contact allergy in humans. 
Eczema patients are usually tested with a baseline series encompassing the most commonly occurring 
contact allergens in the population. By application of the allergen in an appropriate concentration and 
vehicle under occlusion for two days, the patch test provokes a miniature eczema reaction in case the 
individual is sensitized. The patch test allergens are usually applied on normal skin on the back in 
standardized chambers like Finn chambers® (Epitest Ltd Oy, Tuusula, Finland) or IQ-chambers© 
(Chemotechnique Diagnostics, Vellinge, Sweden), secured with tape. Ready-to-use test systems such 
as the Thin-layer Rapid Use Epicutaneous (TRUE) test® is available for a limited number of allergens 
and it is another possiblity. 
The contact allergens used in routine clinic are often formulated in petrolatum, but this vehicle is not 
optimal for every allergen and alternative vehicles can be used when needed. Solvents like water, 
ethanol, propylene glycol and acetone may be used as alternative vehicles increasing the skin 
penetration, but they also have drawbacks as i.e. propylene glycol being a sensitizer and irritant (16). 
Allergens formulated in different vehicles but in the same concentration may produce different 
strength of reactions (8;17). Usually the highest possible concentration that does not produce irritancy 
is used, so the number of false positive and false negative results are minimized (16). For rare 
allergens it is necessary to carefully select the patch test concentration to avoid both false positive and 
false negative reactions. 
Readings are usually done on day 2-3 and on day 5-7 and both readings are important due to some 
early or late occurring reactions. Patch testing has been standardized by recommendation of the 
International Contact Dermatitis Research Group (ICDRG) (16). Patch test reactions are scored by a 
visual reading scale. For a positive patch test is required at least homogeneous redness and infiltration 
in the entire test area, scored as a 1+ reaction, if vesicles are also present the reaction is scored as a 2+ 
reaction, and if coalescing vesicles and spreading is present it is scored as a 3+ reaction. Irritant 
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responses are classified as IR and doubtful reactions as +?. A more detailed reading scale has been 
developed by Hindsen and Bruze (18) and later modified by Fischer et al (19) in order to recognize 
smaller differences in the allergic reactions primary for research purposes.  
4.4.2. Repeated open application test (ROAT) 
The ROAT is a supplementary provocative use test which can be used to confirm the presence of 
contact allergy if the patch test reaction is difficult to evaluate. The ROAT was standardized in 1986 
regarding recommended test site on the body, for influence of skin region, area and application time 
(6;7). The advantage of the ROAT is that it mimics a real life exposure situation and is important in 
determining threshold values for sensitizers in risk assessment which may be more accurate compared 
to patch test thresholds. ROAT and patch test thresholds correlate very well (19-22). In this thesis the 
ROAT was used to investigate the effect of allergens formulated in different vehicles.  
4.5. Skin penetration and absorption of chemicals  – related to 
allergenicity 
In order for a contact allergen to get in contact with the cutaneous immune system it has to penetrate 
into the viable epidermis. Thus allergens should have appropriate physicochemical properties to cross 
the stratum corneum which normally is an effective skin barrier.  A certain degree of lipophilicity 
(logP around 2) is advantageous.  Extremely lipophilic and hydrophilic molecules are poor skin 
penetrators (9;23). Formulating a chemical/allergen in different vehicles for topical administration 
may change the skin penetration profile (25-27) and the sensitizing and elicitation capacity of the 
allergen (8;14;24-26) but how these outcomes are related to penetration and absorption properties are 
not well elucidated. It is important to distinguish between skin penetration and absorption. 
Percutaneous absorption corresponds to the transfer of a substance via the skin from the external 
environment to the systemic circulation. Penetration is a passive diffusion into the epidermis, dermis 
or cutaneous annexes (5). Formulating an allergen in different vehicles for topical administration may 
change the sensitizing and elicitation capacity of the allergen (8;16;29;30). Contact allergens are 
reactive compounds and interact with enzymes in the skin. This may change the availability to the 
Langerhans cells and thus affect sensitization. The strong allergen fluorescein isothiocyanate was 
found mainly to be retained in or adjacent to stratum corneum whereas a structurally similar non 
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sensitizing compound was found to be distributed more diffuse through the epidermis studied by two 
photon microscopy (27). The two compounds have similar lipophilicity and comparable molecular 
weights. The authors concluded that the highly reactive fluorescein isothiocyanate reacts with 
molecules in the skin thus obstructing its further transdermal transport. 
4.6. Common vehicle systems in cosmetic and topical drugs 
The development of new formulations for topical products is a continuing process. Encapsulation of 
product ingredients into different carrier molecules (like liposomes) may improve product efficiency, 
and it is a promising tool for dermal and transdermal delivery of drugs and cosmetic ingredients. The 
encapsulation technology has been used since the late 1960´s and several topical products are 
marketed today claiming benefits from this technology. Bearing the enormous number of research 
papers dealing with encapsulation technologies in mind, surprisingly few pharmaceutical products 
have reached the market. This chapter focuses on the use of different types of encapsulating 
technologies in topical drugs and cosmetics and describes potential effects on product allergenicity. 
 
One advantage of encapsulating a drug into liposomes is the possibility of delivering the drug directly 
to the site of action in the skin at a higher concentration and obtaining a reduced percutaneous 
absorption at the same time. The penetration pattern is determined by the composition of the liposome 
and the encapsulated compound. It is difficult to get approval from health service authorities of topical 
drugs using encapsulation technology because it is problematic for the manufacturer to prove the 
presence and stability of the microvesicles in the product.  Some pharmaceutical products using 
microvesicle carriers are commercially available (Table 1). Examples are Pevaryl Lipogel® 
(econazole encapsulated in liposomes, Cilag Corps, Schaffhausen, Switzerland) and a local anaesthetic 
formulated in liposomes (LMX4™, Ferndale Pharmaceuticals Ltd, UK). Estrasorb™ is estradiol 
encapsulated in micelles in a nanoemulsion for transdermal drug delivery, reducing hot flares in 
menopause women (28). Several clinical trials have shown improved biological effects of products 
with microvesicle formulations compared to conventional formulations (for treatment of herpes 
simplex, psoriasis, acne, xerosis, atopic dermatitis, vitiligo, and superficial thrombophlebitis (29-36)). 
An example is 5-aminolevulinic acid formulated in 50 nm liposomes, which gives a more precise drug 
delivery that  allows  a  40%  reduction  in  the  amount  of  active ingredient  when  used  to  treat  
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acne  with  photodynamic therapy. The liposomes concentrate in the pilosebaceous units thereby 
reducing the side effects and open doors for new treatment modalities (37). Another example is topical 
administration of methotrexate (MTX) which is hydrophilic and present in dissociated form at 
physiological pH. Its capacity for passive diffusion is thus limited. By encapsulating MTX in 
liposomes clinical trials have shown better efficacy compared to placebo and marketed MTX-gel, 
probably due to increased bioavailability (38).  
 
Table 1.  
Commercially available drug delivery systems for the topical therapy of skin diseases and the transdermal application (39). 
aMedical device. 
 
The carrier particles themselves are all considered safe for topical use, but the interaction between the 
carrier particle and the active ingredient may cause biological effects due to altered skin penetration, 
release profile or deposition of the active ingredient.   
Lipid vesicles, solid lipid nanoparticles and polymeric nanoparticles are used in cosmetic formulations 
to increase bioavilability in stratum corneum and to protect light and oxygen sensitive cosmetic 
ingredients against degradation. Cosmetic ingredients like retinyl palmitate may cause physiological 
changes of the skin, but do not claim to treat skin diseases. Examples of encapsulated cosmetic 
ingredients are numerous e.g. coenzyme Q10, ascorbyl palmitate, tocopherol (vitamin E) and retinol 
(vitamin A) (44;45).  
Active compound Vehicle 
Commercial 
product 
Company Indication 
Econazole Liposomes Pevaryl Lipogel 
Cilag, 
Switzerland 
Dermatomycoses 
Methoxycinnamates butyl methoxy-
dibenzoylmethane 
Liposomes 
Daylong 
Actinicaa 
Spirig, 
Switzerland 
Prophylaxis of actinic 
keratosis 
Diclofenac Liposomes Diclac Lipogel Hexal, Germany Osteoarthritis 
Tretinoin Microsponges Retin-A Micro 
Ortho-
Neutrogena, USA 
Acne vulgaris 
Fluorouracil Microsponges Carac 
Sanofi Aventis, 
USA 
Actinic keratosis 
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4.6.1. Liposomes 
Liposomes are produced in sizes ranging from 25 nm to several 
micrometers. They consist of a single or multiple lipid double layer 
(unilamellar or multilamellar vesicles) (Figure 3). Liposomes are 
capable of carrying amphiphilic active ingredients either in the lipid 
layer or in the hydrophilic core. They are believed to protect the 
active ingredients from degradation. Liposomes tend to break down 
into its constituent components when in contact with the skin. 
Therefore, liposomes at best can modulate drug transport to stratum 
corneum, but penetration will require more stable liposomes such as 
solid lipid nanoparticles (40). The concentration in the epidermis of 
active ingredients may increase up to five times administered in 
liposome formulations compared to more conventional vehicles (41). Liposome formulation in water 
can easily be incorporated in an aqueous cream for better cosmetic performance. Examples of active 
ingredients incorporated in liposomes in cosmetic industry are antioxidants, vitamin A derivatives and 
vitamin E.  
4.6.2. Transfersomes™ 
When adding different amounts of so called edge activator to the bilayer of classical liposomes eg. 
cholesterol or sodium cholate and a small concentration of ethanol these vesicles are called 
Transfersomes™ or Flexosomes™. The edge activators destabilise the membrane creating a more 
flexibile structure and have been shown to penetrate in stratum corneum better compared to classical 
liposomes, thereby deliver their encapsulated ingredients deeper in the epidermis but not to the blood 
circulation (42). The mechanism of enhancement of skin penetration is not completely elucidated, but 
because of the flexibility of Transfersomes™, they are believed to squeeze between the corneocytes 
driven by an osmotic force due to the difference in water content of the relatively dehydrated 
epidermis compared to the viable dermis (43). No evidence supporting this theory have been published 
though. Because of that theory, Transfersomes™ should not be applied under occluded conditions 
which abolished the osmotic effect. Several drugs encapsulated in transfersomes have been tested in 
Figure 3.  
Model of a unilamellar liposome 
consisting of one double lipid 
bilayer. 
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animal experiments (eg. NSAID and local anaesthetics) showing increased dermal delivery and 
clinical effect compared to conventional formulations (42).  
4.6.3. Ethosomes 
Ethosomes (ethanolic liposomes) are made of phospholipids, a high content of ethanol (20-50%) and 
water. They deliver encapsulated drugs to the deep skin layers and the systemic circulation. Ethosomes 
have a much higher loading capacity of lipophilic drugs compared to classic liposomes. A clinical trial 
in humans has shown that treatment with ethosomal encapsulated acyclovir significantly improved a 
herpetic infection compared to the traditional Zovirax™ cream of the same concentration of active 
drug. Insulin loaded ethosomes has been found suitable for systemic transdermal delivery and the 
antibiotic bacitracin has likewise been encapsulated in ethosomes reaching the deep layers of the skin 
in animal experiments (44). Ethosomes may play a role in future transdermal drug delivery.Examples 
of cosmetics using ethosomes are LipoductionTM and NoicellexTM  
4.6.4. Niosomes 
Niosomes consists of non-ionic surfactant vesicles and are an alternative to liposomes. They can 
entrap both hydrophilic and hydrophobic chemicals, enhance the delivery to the skin and sustain the 
release of the drug. A phase I and II study in psoriasis patients concludes that methotrexate loaded 
niosomes are more efficacious than marketed methotrexate gel (38).  
4.6.5. Solid lipid nanoparticles 
Solid lipid nanoparticles have been developed in the 1990s and are produced by replacing the liquid 
lipid in an oil in water emulsion with a solid lipid (both at room and body temperature). Incorporation 
of pharmaceuticals and cosmetics in solid lipid nanoparticles is feasible and can easily be formulated 
in a cream (45). An advantage of solid lipid nanoparticles compared to conventional creams is an 
increase in skin hydration due to a better occlusive effect by solid lipid nanoparticles (46). Burst or 
sustained release of incorporated ingredients have been reported as well as increased percutaneous 
absorption compared to conventional formulations and is probably due to the unique composition of 
the solid lipid nanoparticles and incorporated ingredient. Examples of pharmaceuticals formulated in 
solid lipid nanoparticles are podophyllotoxin, antimycotics, non steroidial anti inflammatory drugs, 
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psoralen and topical glucocorticoids. No human studies with pharmaceuticals incorporated in solid 
lipid nanoparticles have been performed yet, but in 2008 more than 30 cosmetic products containing 
solid lipid nanoparticles were market (47). No side effects have been reported.  
4.6.6. Nanoemulsions 
Nanoemulsions consist of two phases with droplets of 50-100nm in the external phase. Emulsifiers 
used to bind together oil and water in products such as hair conditioner and makeup remover yield a 
less oily mixture when they are broken down into nanoparticles. Nanoemulsions are used in both 
rinse-off and stay-on products. Different results are obtained on skin penetration and its correlation 
with droplet size. Nanoemulsions increase transdermal bioavailability of Vitamin E (48), but 
penetration of tetracaine from a nanoemulsion was not affected by droplet size on the skin within the 
range from 100-3500nm (49). Different emulsion components have been used and other authors have 
found increasing transdermal penetration with decreasing droplet size. There is so far no simple 
relationship between chemical, particle size and penetration, and 
each new emulsion carrying different active ingredients must be 
investigated separately to characterize skin penetration pattern. 
Estrasorb™ is an emulsion of estradiol nanoparticles and 
soybean oil which is on the market for treating hot flares of 
menopausal women (28). 
4.6.7. Nanospheres 
Nanospheres are produced from different polymers e.g 
polycaprolactone, a biodegradable product widely used in 
cosmetic industry. When produced, the polymer wrap around 
itself, creating lipo- and hydrophilic spaces (Figure 4). Several 
drugs have been incorporated in nanospheres (50) as well as 
cosmetic ingredients (51). LÓreal has developed a nanocarrier 
system called Nanosome™ consisting of the biodegradable 
polymer polycaprolactone and other cosmetic companies have 
Figure 4. 
Scanning electron microscopy of a 
nanosphere loaded with Paclitaxel (A) 
and unloaded (B). Picture from Wang et 
al. (54) 
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developed similar products from other polymeric particles. Polycaprolactone nanoparticles loaded with 
the lipophilic dying agent Nile Red showed enhanced penetration of the molecule into the stratum 
corneum layers (up to 60µm), compared to non-nano particle formulation (59;60). The distribution of 
another topically applied nanosphere-Nile Red formulations was studied by Sheihet et al in human 
cadaver skin using cryosectioning and fluorescence microscopy  (52). Permeation analysis revealed 
that the nanospheres delivered nine times more Nile Red to the lower dermis than a control 
formulation using propylene glycol. Few papers have been published on the skin 
penetration/absorption behaviour and clinical effect of carrier molecules manufactured by cosmetic 
companies. 
 
4.6.8. Mechanism of penetration enhancement 
It is difficult to establish how vesicular 
drug delivery systems behave 
individually once applied to the skin and 
the exact mechanism is not known. 
However different scenarios have been 
proposed. (a) Particle constituents may 
act as penetration enhancers after 
particle disruption on skin surface and 
subsequently alter the skin lipid lamellae within the skin layer, (b) particles may serve as a depot of 
sustained release of dermally active compounds or (c) particles may serve as a rate limiting membrane 
barrier for the modulation of systemic absorption, hence providing a controlled transdermal delivery 
system(54). Another possibility is that intact vesicles penetrate beyond the superficial layers of the 
skin, but this is still a matter of discussion. Some theories state that intact Transfersomes™ and 
ethosomes may penetrate into the deeper layers of the skin and maybe even through the skin due to 
their elasticity (Figure 5). Several published studies have shown conflicting results and the theory is 
still very controversy (42;53).  
 
 
Figure 5.  
Suggested mechanism of transdermal penetration of ethosomes 
which is believed to be caused by the increased elasticity due to the 
ethanol content. The theory has been tested in several studies with 
conflicting results and is still very controversy (53). 
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5. Aims of project 
The project is based on the hypothesis that formulation of contact allergens in drug delivery systems 
using encapsulating technologies may affect the sensitizing and elicitation capacity of contact 
allergens. Few clinical reports have suggested that carrier molecules for ingredients in topical products 
have boosted the development of allergic contact dermatitis to the ingredient in question. Liposomes 
with encapsulated propyl gallate  have been suggested to boost the development of contact allergy to 
propyl gallate in thirteen patients. However, patch tests with and without the liposomal formulation 
were not performed (55). Further, a case report described a woman developing severe allergic contact 
dermatitis from an anti wrinkle cream containing retinyl palmitate encapsulated in polycaprolactone 
(Figure 6) (51). Polycaprolactone is a polymeric drug delivery system capable of encapsulating lipo- 
and hydrophilic agents. Retinyl palmitate is a rare contact allergen, and diagnostic patch tests revealed 
that the patient reacted more strongly to encapsulated retinyl palmitate compared to retinyl palmitate 
in petrolatum, even though the retinyl palmitate concentration was much lower when formulated in 
polycaprolactone compared to the petrolatum formulation. 
The aim of this thesis is to investigate the effect of encapsulation of selected contact allergens in 
topical drug delivery systems with regard to sensitization and elicitation capacity of the allergens. 
Furthermore, laboratory experiments were performed to elucidate the relationship between 
percutaneous absorption of contact allergens and the sensitization properties of allergens formulated 
with and without encapsulation in ethosomes. 
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Figure 6.  
Patch test results of retinyl palmitate (RP) in petrolatum (pet), encapsulated retinyl palmitate in polycaprolactone 
(PCL) and pure PCL.  RP 5% in petrolatum showed a + rection, PCL: negative and RP in PCL: ++. Note that RP 
in PCL is in a much lower concentration compared to RP in petrolatum (confidiential information). 
Encapsulating RP in PCL increased the patch test reactions. 
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5.1. Sensitization studies with three contact allergens encapsulated 
in three different carrier systems using the mouse Local Lymph 
Node Assay (paper I and II) 
Isoeugenol, dinitro-chloro-benzene and potassium dichromate were encapsulated in liposomes, 
ethosomes and in the microsphere “polycaprolactone”. These preparations were investigated for 
sensitizing properties in a controlled design. Further, the impact of the size of liposomes was studied.  
 
5.2. Elicitation studies in sensitized human volunteers with 
isoeugenol and methyldibromoglutaronitrile formulated in 
ethosomes (paper III) 
The encapsulated contact allergens in ethosomes were patch tested using a dilution series in volunteer 
patients in comparison with the same allergens in a control vehicle without ethosomes.  Furthermore, a 
repeated open application test was performed in a subgroup of volunteers comparing the response to 
the contact allergens formulated with and without ethosomes.  
 
5.3. Skin penetration properties and release kinetics of the contact 
allergens encapsulated in ethosomes (paper IV) 
It is known that formulation of contact allergens in different vehicles may alter the sensitizing and 
elicitation capacity of contact allergens, but the relationship between sensitization response and 
percutaneous absorption/penetration is not clear. This study examined the percutaneous absorption and 
penetration of dinitro-chloro-benzene and isoeugenol formulated in ethosomes and ethanol:water using 
human cadaver skin mounted on Franz cells. 
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6. Methods 
6.1. Allergens 
The contact allergens and carrier systems used in the project were selected to fulfill certain criteria:  
The contac allergens had to be strong sensitizers due to limited encapsulating capacities of the carrier 
molecules and at the same time be common causes of allergic contact dermatitis so volunteer 
sensitized patients from the Department of Dermatology and Allergy Centre, Odense University 
Hospital, could be recruited for challenge studies. Further we wanted to test both lipophilic and 
hydrophilic contact allergens in order to see if the solubility played a role (and thereby the storage of 
the contact allergen in the vesicles) in the generation of contact allergy. 
The carrier systems should be well defined and commonly used by the industry either on the market or 
in research phases.  
Four strong contact sensitizers: potassium dichromate, isoeugenol, methyldibromo glutaronitrile and 
dinitrochlorobenzene were selected, also because quantitative methods for chemical analyses were 
available. The compounds were encapsulated in three selected drug delivery systems relevant for 
topical use were chosen: liposomes which are widely used in cosmetic and pharmaceutical research 
industry, ethosomes (ethanolic liposomes) because they contain ethanol allowing for a control solution 
of a lipophilic allergen in an ethanol:water mixture, making the lipids the only difference between the 
two solutions, and finally polycaprolactone ,which is a polymeric particle used to encapsulate retinyl 
palmitate in an anti wrinkle crème (51). 
The dermatotoxicologic risks from skin exposure to these carrier systems are considered low. 
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6.2. Preparation and validation of test solutions 
6.2.1. Allergen loaded carrier systems 
Ethosomes loaded with allergens were prepared as described 
by Touitou (56). Briefly, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), Avanti Polar Lipids (Alabaster, 
USA) was dissolved in 96% ethanol (pure or containing 
isoeugenol (Aldrich Denmark (CAS: 97-54-1)), dinitro-
chloro-benzene (CAS No 97-00-7, Sigma-Aldrich, 
Denmark)) or methyldibromogutaronitrile (Alfa-Aesar, 
Karlsruhe, Germany (CAS no 35691-65-7))  and MilliQ 
water (either pure or containing potassium dichromate 
(analytical grade, Alfa Aesar, London, UK, CAS: 7778-50-
9)) was added slowly to a final concentration of 40% (v/v) 
ethanol under magnetic stirring (700 rpm). The final 
concentration of the allergens was measured by High-
Performance Liquid Chromatography. The suspension was 
stirred for 5 minutes and then extruded 10 times through two 
polycarbonate filters with a pore size of 50, 100 or 200 nm using a Lipex® Extruder (Northern Lipids 
INC.). Empty ethosomes and an ethanol:water solution (4:6) of a corresponding concentration of 
allergen were used as control substances.  
 
Liposome preparation was made by the thin film method. Briefly POPC and isoeugenol or dinitro-
chloro-benzene were dissolved in chloroform and methanol (2:1, v/v) in a 250-ml round-bottomed 
flask. The mixture was evaporated in a rotary evaporator above the transition temperature of the 
phospholipids and solvent traces were removed under vacuum. The thin film was hydrated with MilliQ 
water (pure or containing potassium dichromate) for 30 min. The vesicle suspension was extruded 
Figure 7. 
Extrusion of liposomes through a nanopore 
filter. 
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through a 50, 100 or 200nm polycarbonate filter 10 times using the Lipex® Extruder (Figure 7) and 
allergen concentration was determined by High-Performance Liquid Chromatography. 
 
Polycaprolactone (CAS no: 2498-41-4, Aldrich, 
Denmark) was dissolved in acetone (pure or 
containing isoeugenol or dinitro-chloro-
benzene) at 45ºC and injected in MilliQ water 
containing 0,17g Pluronic F-68™ (CAS 9003-
11-6, Aldrich, Denmark) (and potassium 
dichromate in certain cases) in a round 
bottomed flask under magnetic stirring (1200 
rpm) at room temperature (Figure 8). Acetone 
and a large amount of the aqueous phase were 
eliminated under reduced pressure to a final 
volume of 5 ml. Allergen concentration was 
measured by High-Performance Liquid 
Chromatography. All formulations were kept 
at 5ºC. A surfactant (Poly(ethylene glycol)-
block-poly(propylene glycol)-block-
poly(ethylene glycol), CAS nr: 9003+11-6, 
Aldrich, Denmark) was added to a final 
concentration of 1% (w/v) to liposome and 
polycaprolactone batches immediately before 
each Local Lymph Node Assay experiment to 
ensure sufficient contact with the skin.  
The concentrations of allergens were 
determined by High-Performance Liquid 
Chromatography to make sure the control solution matched the formulation containing 
polycaprolactone. 
Figure 8. 
Manufacturing of polycaprolactone particles loaded with 
potassium dichromate.  
 
Figure 9. 
Example of size measurement of liposomes loaded  
with dinitro-chloro-benzene extruded through a filter of 100 nm 
pore size. A Gaussian distribution is seen with a mean  
diameter of  96 nm. 
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Dynamic light scattering  
Hydrodynamic particle diameters and polydispersity index of ethosomes were determined by dynamic 
light scattering using a BI-200SM from Brookhaven Instruments. This incorporates a 632.8 nm HeNe 
laser operated at a fixed scattering angle of 90°. A sample of 10 µl was diluted in 1190µl 40% 
ethanol:MilliQ water mixture or pure MilliQ water dependent of the original vehicle. The 
measurements were conducted in triplicate; in a multimodal mode of 120 s. Figure 9 shows an 
example of the size distribution of extruded liposomes through a 100 nm pore size filter.  
6.2.2. Encapsulation efficiency 
The  encapsulation efficiency (EE%) of allergens formulated in polycaprolactone, ethosomes and 
liposomes was determined by ultracentrifugation as described by Heeremans et al. (57). Ethosomal, 
polycaprolactone and liposomal preparations containing dinitro-chloro-benzene, isoeugenol, 
methyldibromoglutaronitrile or potassium dichromate were kept overnight at 5°C where after they 
were spun at 40.000 RPM for three hours in an Hitachi Sorvall Discovery 90SE ultracentrifuge with a 
swingout rotor from Sorvall (SW50.1). The supernatant was immediately removed and drug quantity 
was determined in both the sediment and the supernatant. Binding efficiency was calculated as 
follows:  [(T-C)/T]*100,  where  T  is  the  total  amount  of  chemical detected in both the supernatant 
and sediment, and C is the amount of chemical detected only in the supernatant. The procedure was 
done in triplicates. 
6.2.3. Quantification of isoeugenol, dinitro-chloro-benzene and potassium 
dichromate 
High-Performance Liquid Chromatography analysis was conducted on an ultimate 3000 series from 
DIONEX™ with a diode array detector. A DIONEX Acclaim®Surfactant column was used to 
separate isoeugenol and dinitro-chloro-benzene (Figure 10). Potassium dichromate was separated 
using a DIONEX Acclaim® 300 C18 column. The temperature of the column and the sample rack in 
the autosampler was set to 20°C. Mobile phase used for dinitro-chloro-benzene and isoeugenol: 75% 
methanol, 25% MilliQ water; isocratic elution for 30 min; and flow rate of 1 ml/min. The separations 
were monitored at 270nm. Mobile phase used for potassium dichromate consisted of 20% methanol 
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for 10 minutes followed by a linear gradient of 90% 
methanol performed over 5 min, followed by 40 min 
of 100% methanol to wash the column and 5 min of 
20% methanol to equilibrate the column for the next 
run. Potassium dichromate was monitored at 260 
nm. Pure reference compounds were used to make 
external calibration curves from which the 
concentrations of allergen were determined.  
6.2.4. Quantification of 
methyldibromoglutaronitrile 
Methyldibromogutaronitrile is not UV-active and 
content was measured by evaporative light scattering detection (Varian 385-LC) using a reversed 
phase C-5 column from Supelco©. Separation was achieved using a 0.8 ml/min flow rate with an 
isocratic mobile phase of 75% methanol and 25% MilliQ water Injection volume was 50µl and 
external calibration was done by pure methyldibromogutaronitrile. 
6.2.5. Sensitization experiments 
The Local Lymph Node Assay was performed according to standard procedure (58) with  the lymph 
node cell proliferation determined for each animal and expressed as mean disintegrations per minute. 
Female CBA/Ca mice purchased from Harlan (Netherlands) 8 weeks of age were housed in cages with 
hepa-filtered airflow, under conventional conditions in light-, humidity- and temperature controlled 
rooms with food and water ad lib. Test substances were applied on the dorsum of both ears of each 
mouse for three consecutive days. On day five [methyl-3H]-thymidine was injected in the tail vein and 
after five hours the mice were sacrificed and the draining lymph nodes removed. A single cell 
suspension from each mouse was made and after two washing procedures with phosphate buffered 
saline, the DNA was precipitated with trichloroacetic acid for 18 hours and the thymidine 
incorporation was measured using β-scintillation counting. The standard vehicle in the Local Lymph 
Node Assay is acetone-olive oil (4:1) which dissolves polycaprolactone particles, ethosomes and 
liposomes. Therefore, we modified the Local Lymph Node Assay by using either water:ethanol (6:4 
Figure 10. 
HPLC diagram of quantification of dinitro-chloro-
benzene. Peak is seen at 6.458 minutes. Area under the 
curve is automatically generated for further calculation of 
concentration. 
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v/v) as control vehicle for ethosomes or water added 1% surfactant as control vehicle for liposome and 
polycaprolactone preparations loaded with hydrophilic allergens making the drug delivery system the 
only difference between batches. Lipophilic allergens were dissolved in ethanol:water (4:6, v/v), 
propylene glycol (analytical grade ,CAS 57-55-6, Riedel-de Haën) or aceone:olive oil (acetone, 
analytical grade purchased from Aldrich, Denmark CAS 67-64-1 and olive oil purchased from Fluka, 
Denmark, CAS 8001-25-0) making the comparison with the drug delivery systems less comparable. 
The experiments were in accordance with Danish and European animal welfare regulations and were 
licensed by the Danish Animal Experimentation Inspectorate. 
6.2.6. Test subjects 
The inclusion criteria were: age over 18 years, a previous positive patch test to 
methyldibromoglutaronitrile or isoeugenol within the last ten years at the Department of Dermatology, 
Odense University Hospital, University of Southern Denmark.  Exclusion criteria were: active eczema 
on test sites, not being able to co-operate to the repeated open application test, pregnancy, and breast 
feeding.  
48 persons with a previous positive patch test to isoeugenol and 89 persons with a previous positive 
patch test to methyldibromogutaronitrile were invited. The study was performed according to the 
Helsinki II declaration and approved by the local Ethics Committee (The Southern region of Denmark, 
S-20090022). 
 
6.2.7. Patch test 
3 concentrations of methyldibromogutaronitrile and 2 concentrations of isoeugenol formulated in 
ethosomes and ethanol:water and blank controls were tested. The placement of the test concentrations 
and vehicles in both tests were randomized and blinded for the investigator and the subjects. After 
termination of the study the randomization code was broken.  The study was performed according to 
the Helsinki II declaration and approved by the local Ethics Committee (The Southern region of 
Denmark, S-20090022). The patch tests were applied on IQ-chambers (Chemotechnique® 
Diagnostics, Sweden), occluded for two days and the reactions were read on D3. The reading scale 
developed by Fischer et al (19) was chosen in order to recognize smaller differences in the allergic 
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responses. The scale was as follows: 0 = no reaction; 1 = few papules with no erythema, no 
infiltration; 2 = faint erythema with no infiltration or papules; 3 = faint erythema with few papules and 
no homogeneous infiltration;  4 = erythema, homogeneous  infiltration;  5 = erythema,  infiltration  
and  a few papules; 6 = erythema, infiltration and papules; 7 = erythema, infiltration, papules and a 
few vesicles; 8 = intensive erythema, infiltration and vesicles. The author performed all readings. All 
formulations were kept in darkness at 5°C and all preparations were made no more than 5 days prior to 
beginning of the patch testing and repeated open application test. Volunteers were instructed to keep 
the test material for the repeated open application test in the refrigerator. The concentrations of 
isoeugenol were: 0.0, 2.80, and 6.54 mg/ml and of methyldibromoglutaronitrile: 0.00, 0.10, 0.21, and 
0.63mg/ml. 
 
6.2.8. Repeated open application test (ROAT) 
Repeated open application tests’ were performed with one concentration of allergen formulated in 
ethosomes and ethanol:water. Two 3x3 cm areas on the volar aspect of both forearms were used. 
Twenty microlitres  of test preparation were  applied  two (methyldibromoglutaronitrile) or three times 
(isoeugenol) daily  using  a  micropipette  (Acura 815, 20 µL, Buch & Holm A ⁄S, Herlev, Denmark) 
with a fixed volume. Test subjects received 2 marked bottles, each mark referring to a test area. The 
solutions were spread on the area with the tip of the pipette and allowed to dry by evaporation. The 
subjects received written instructions and were instructed orally and manually in using the pipette. The 
dose of one application was 5.66 mg/ml isoeugenol or 0.10mg/ml methyldibromoglutaronitrile. When 
an area showed a positive reaction (verified by investigator), the subjects stopped application on that 
test area and continued on the other area. A reaction was defined as positive when 70% of the area had 
erythema, papules, or vesicles. Numbers of days until positive reactions occurred were counted. The 
author performed all readings. If no reaction developed within 4 weeks, application was stopped 
(except in one case: Here the repeated open application tests on one arm were positive after 18 days 
and on the other after 45 days). The concentration of isoeugenol was 5.66 mg/ml and of 
methyldibromoglutaronitrile: 0.10 mg/ml. 
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6.2.9. Skin penetration and absorption model 
Skin Membranes  
The human skin samples were obtained from the Department of Plastic and Reconstructive Surgery, 
Odense University Hospital. Skin was sampled from three women (26-37 years old) who underwent 
breast reconstruction. Skin samples were kept at -20°C for periods not exceeding 12 months. The skin 
was allowed to thaw at room temperature 1 hour before being cleaned with distilled water. 
Subcutaneous fat was removed. Skin thickness varied between 0.90 and 0.96 mm. Skin samples from 
individual donors were equally distributed between experimental groups. 
Skin penetration and absorption model 
Percutaneous penetration experiments were 
carried out using Franz diffusion cells with a 
permeation area of 2.12 cm2 and a receptor 
volume between 15 and 19 ml (measured for 
each individual cell) as described by Nielsen 
et al (23).  The system consists of two half-
cells where the upper cell compartment 
represents the donor chamber and the lower 
the receptor chamber (Figure 11). The cells 
were kept at a constant temperature (32°C) in 
a water bath with individual magnetic stirring. 
Prior to experiments, the epidermal site was 
exposed to ambient laboratory conditions and 
the dermis was exposed to an aqueous solution of 0.9% NaCl and 5% bovine serum albumin 
containing 10% ethanol for 18 hours. Further, the barrier integrity was evaluated by capacitance 
measurements (Lutron DM-9023, Acer AB, Sweden) before the exposure to test substances, and cells 
with a capacitance above 110 nF were excluded. 
Figure 11. 
Franz cell chamber used with human cadaver full 
thicknes skin (A). 106µl sample is applied on the donor 
side (B) and samples from receptor chamber were taken 
at selected time intervals (note the parafilm occlusion to 
prevent evaporation) (C). Epidermis is gently separated 
from dermis for individual allergen measurement (D).   
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During the experimental periods, donor and receptor chambers were covered with parafilm to avoid 
evaporation. The skin was exposed to 106µL test substance (50 µL/cm2) and samples of 1 mL where 
taken at 2, 4, 6, 12, and 24 hours from the receptor chamber and replaced with 1 mL of fresh receptor 
fluid. At the end of experiment, remaining test compound in the donor chamber and on top of the skin 
was sampled using repeated washings with cotton swabs and 50% acetonitrile. Cotton swabs and skin 
samples were left for 72 hours to extract in acetonitrile before chemical analysis. 
After termination of experiments, the epidermis was gently removed from the skin samples with a 
sharp knife, and both dermis and epidermis were transferred to individual vials containing 100% 
acetonitrile and left for extraction for 72 hours before measuring the amount of dinitro-chloro-benzene 
or isoeugenol.  
The adherence of test compounds to glass in the receptor chamber, to proteins in the receptor fluid, 
and to the skin after extraction procedures was evaluated to assure complete recovery of penetrated 
test compounds.  
The amount of dinitro-chloro-benzene applied in ethanol:water was 0.035 mg and 0.036 mg in 
ethosomes. The amount of isoeugenol applied in ethanol:water was 1.58 mg and 1.24 mg when 
applied in ethosomes.  
6.2.10. Release kinetics of allergens from ethosomes 
Dialysis membranes (Spectra-por 6, pore size: 10 000 Daltons, Spectrum Labs, purchased from Bie & 
Berntsen AS, Herlev, Denmark) were filled with 300µL test solution of dinitro-chloro-benzene or 
isoeugenol formulated in ethanol:water, 30, 60 or 90 mg/mL ethosomes and left in 75mL  
ethanol:water (4:6 v/v) covered with parafilm on a magnetic stirrer . Samples of 500µL were taken out 
at specific time intervals (Figure 12) and replaced with an equal amount of ethanol:water. Samples 
were analysed by high pressure liquid chromatography and expressed as % of the applied amount of 
allergen. The concentration of dinitro-chloro-benzene was 0.79 mg/mL in ethanol:water , 0.67 mg/mL 
in 30mg/ml ethosomes, 0.62 mg/mL in 60mg/mL ethosomes, and 0.63 mg/mL in 90 mg/mL 
ethosomes. The concentration of isoeugenol was 8.79 mg/mL in ethanol:water, 8.79 mg/mL in 
30mg/mL ethosomes, 7.23 mg/mL in 60mg/mL ethosomes, and 7.63 mg/mL in 90 mg/mL ethosomes. 
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A T50% value was calculated in a similar way 
as the EC3% value of the Local Lymph Node 
Assay (59), now estimating the time needed for 
50% of the allergen to diffuse through the 
dialysis membrane.  
6.3. Statistical data analysis 
Results are expressed as means ±Standard 
deviation (SD) or standard error of mean 
(SEM). Statistically significant differences in 
the Local Lymph Node Assay experiments were 
determined using One Way ANOVA and 
Student-Newman-Keuls test for post hoc 
analysis. Differences in the patch test reactions 
and percutaneous absorption experiments were 
determined by two-way analysis of variance (two-way ANOVA) using applied dose and vehicle 
(ethosomes/ethanol:water) as factors. Repeated open application test experiments were analysed by 
Wilcoxon Signed Rank Test. Statistically significant differences of penetration over time of isoeugenol 
and dinitro-chloro-benzene and the release kinetics of allergens from ethosomes were determined 
using Two Way ANOVA. Mann Whitney test was used to test for different amount of allergen stored 
in epidermal and dermal compartments for ethanol:water and ethosome formulations. P< 0.05 was 
chosen as minimal level of significance. The statistical software package: ”Graphpad Prism 4” from 
GraphPad Software inc. San Diego, California, USA was used. 
 
Figure 12.  
Dialysis of liposome formulation of potassium dichromate. 
The lower left picture shows the formulation before (right)  
and after (left) dialysis.  
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7. Experimental results and discussion 
7.1. Sensitization studies (paper I & II) 
7.1.1. Results 
Empty ethosomes, liposomes, polycaprolactone particles and the surfactant did not sensitize 
themselves in the Local Lymph Node Assay (Table 2, 3 and 4). Ethosomes, liposomes and 
polycaprolactone encapsulated with potassium dichromate showed no significant effect on the 
sensitizing capacity compared to potassium dichromate in ethanol:water or MilliQ water added 1% 
surfactant (Table 2). Dinitro-chloro-benzene and isoeugenol loaded polycaprolactone particles and 
dinitro-chloro-benzene in propylene glycol showed a significantly reduced sensitisation response 
compared to dinitro-chloro-benzene and isoeugenol in liposomes, acetone:olive oil and ethanol:water 
(Table 3 and 4). As opposed to the above results isoeugenol and dinitro-chloro-benzene loaded 
ethosomes showed a significant increased sensitizing capacity compared to formulations without 
ethosomes, and the dose of ethosomes was an additional factor as there was a linear dose-response 
relationship between concentration of ethosomes and the sensitization obtained, reaching a significant 
level at 60 mg/ml POPC (60). The size of dinitro-chloro-benzene loaded liposomes did not affect their 
sensitizing capacity but dinitro-chloro-benzene loaded ethosomes enhanced the allergenicity compared 
to a solution of dinitro-chloro-benzene, ethanol, water and POPC (larger vesicles) (Table 3). The effect 
of the surfactant on the sensitizing capacity is seen in Table 5. The surfactant is not a sensitizer but 
increases the sensitizing capacity of the potassium dichromate formulation by a factor of two when 
doubling the surfactant concentration. Table 6 shows the size of vesicles and the encapsulation 
efficiency.  The encapsulation efficiency is low for potassium dichromate (0.7-16%) and in a higher 
range for dinitro-chloro-benzene and isoeugenol (77-98%).  
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Table 2.   
Results of Local Lymph Node Assay experiments performed with potassium dichromate in 
different vehicles.  §surfactant 1% added. Statistical differences were calculated by one way 
ANOVA and Student-Newman-Keuls test for post hoc analysis with P<0.05 as minimal 
level of significans.  ***P<0.001. 
 
Potassium dichromate 
[Lipid], (n) 
Allergen % 
(w/v) 
Lymphocyte 
proliferation 
(mean DPM ± SD) 
Ethanol:water (5) 0.5 6933±3833 
Ethosomes (5) 0.5 5049±1329 
   
Polycaprolactone (50mg/ml) (6)§ 0,0 428±181*** 
Polycaprolactone (50mg/ml) (7)§ 0.5 1999±1184 
Polycaprolactone (5mg/ml) (6)§ 0.5 2231±2167 
Water (5)§ 0.5 2165±1018 
   
Liposomes (80mg/ml) (5)§ 0.0 1198±611*** 
Liposomes (40mg/ml) (5)§ 0.5 4343±1377 
Liposomes (80mg/ml) (5)§ 0.5 4843±1339 
Water (4)§ 0.5 4987±3069 
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Table 3. 
Results of Local Lymph Node Assay experiments performed with dinitro-chloro-benzene in different 
vehicles.  §wetting agent 1% added.  Statistical differences were calculated by one way ANOVA and 
Student-Newman-Keuls test for post hoc analysis with P<0.05 as minimal level of significans. 
*P<0.05, **P<0.01, ***P<0.001. 
 
Dinitro-chloro-benzene [Lipid], (n) 
Allergen 
% (w/v) 
Lymphocyte 
proliferation 
(mean DPM ± SD) 
Ethanol:water (5)# 0.03 1349±443* 
Ethosomes (60mg/ml) (5)# 0.03 2151±925** 
Ethosomes (60mg/ml) (5)# 0.00 387±108 
   
Ethanol:water (6)# 0.04 1017±290 
Ethanol:water:POPC (60mg/ml) (6)# 0.04 3912±310 
Ethosomes (60mg/ml) (4)# 0.04 6007±944 
Ethosomes (60mg/ml) (5)# 0.00 575±165 
   
Polycaprolactone (60mg/ml) (5)§ 0.05 1211±449 
Liposomes (60mg/ml)(5)§ 0.05 7602±2658*** 
Ethanol:water (5) 0.05 5349±2151*** 
Acetone:olive oil (5) 0.05 5633±666*** 
Polycaprolactone (60mg/ml) (5)§ 0.00 778±234 
   
Liposomes (60mgml) (6)§ not extruded 0.04 1785±705 
Liposomes (60mgml) (6)§ 200nm 0.04 2106±391 
Liposomes (60mgml) (6)§ 100nm 0.04 2923±626 
Liposomes (60mgml) (6)§ 50nm 0.04 1806±514 
 
 
 
 
*
***
***
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Table 4.  
Results of Local Lymph Node Assay experiments performed with isoeugenol in different 
vehicles. n= number of mice. DPM=disintegrations per minute. §Surfactant 1% added. 
Statistical differences were calculated by one way ANOVA and Student-Newman-Keuls test for 
post hoc analysis with P<0.05 as minimal level of significance. *P<0.05, **P<0.01, 
***P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.  
Results of Local Lymph Node Assay experiments performed with potassium 
dichromate dissolved in water added a surfactant. Adding a surfactant agent to 
potassium dichromate dissolved in water increased the sensitizing capacity of the 
Local Lymph Node Assay. Lymph nodes were pooled for each group. 
 
Sample description Potassium dichromate (% w/v) 
Lymphocyte 
proliferation 
Surfactant 2% (n=4) 0.0 3419 
Surfactant 1% (n=4) 0.5 7372 
Surfactant 1% + (n=4) 1.0 16074 
Surfactant 2% + (n=4) 0.5 15737 
 
 
 
 
Isoeugenol 
[Lipid], (n) 
Dose  
% (w/v) 
Lymphocyte proliferation 
(mean DPM ± SD) 
Ethanol:water (7) 1.5 641±349 
Ethosomes (60mg/ml) (6) 1.5 2343±533*** 
Ethosomes (60mg/ml) (6) 0.0 777±420 
   
Ethanol:water (5) 1.5 569±289 
Ethosomes (20mg/ml) (5) 1.5 850±124 
Ethosomes (40mg/ml) (5) 1.5 1053±289 
Ethosomes (60mg/ml) (5) 1.5 1359±531* 
   
Polycaprolactone (50mg/ml) (5)§ 1.3 1100±406 
Liposomes (60mg/ml) (5)§ 1.3 3868±950*** 
Acetone:olive oil (5) 1.3 4491±819*** 
Propylene glycol (5) 1.3 861±346 
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Table 6. 
Size and encapsulation efficiencies of different drug delivery systems loaded with potassium dichromate, dinitro-chloro-
benzene (DNCB) or isoeugenol. Results are mean±SD. n=3 in all experiments.   
 
Sample description Allergen Size±SD (nm) Encapsulation efficiency % ±SD  
Polycaprolactone Potassium dichromate 313±13 0.7±0.3 
Liposome Potassium dichromate 91±5 7±2.1 
Ethosome Potassium dichromate 436±9 16±0.4 
Polycaprolactone DNCB 231±20 83±0.6 
Liposome DNCB 120±17 92±0.1 
Ethosome DNCB 245±17 90±0.3 
Polycaprolactone Isoeugenol 343±21 84±0.1 
Liposome Isoeugenol 155±25 98±0.1 
Ethosome Isoeugenol 396±20 77±0.3 
 
 
 
7.1.2. Discussion 
For the first time it is shown that contact allergens encapsulated in ethosomes can show enhanced 
sensitizing capacity compared to the same allergen concentration in solution. Encapsulated isoeugenol 
in ethosomes showed repeatedly, significantly increased sensitization in a modified Local Lymph 
Node Assay compared to isoeugenol in solution. Isoeugenol has previously been tested in the Local 
Lymph Node Assay in different vehicles and the EC3 values obtained were 0.9 (dimethylsulfoxide), 
1.5 (acetone:olive oil), 1.8 (ethanol:water 1:9), 2.5 (propylene glycol), and 4.9 (water/ethanol 1:1) 
(25). The dose of isoeugenol (1.1% w/v) in the present experiments was selected due to limited 
solubility of isoeugenol in the ethanol:water solution. Higher concentrations were not possible due to 
instability of the ethosome formulation with change in vesicle size and polydispersity index. The 
isoeugenol concentration is thus below the EC3 values reported from other Local Lymph Node Assay 
experiments with isoeugenol using ethanol:water as vehicle. In accordance with this, isoeugenol did 
not sensitize in the ethanol:water solution, only in the ethosome formulation. Dinitro-chloro-benzene 
is a more potent allergen which permitted a concentration above its EC3 value. Dinitro-chloro-benzene 
0.03% (w/v) showed stronger sensitization in the ethanol:water solution compared to empty ethosomes 
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and the sensitization was further enhanced when formulated in ethosomes. However, the presence of 
POPC in the dinitro-chloro-benzene ethanol:water solution (0.04%) without extrusion of ethosomes 
also had an enhancing effect on sensitization compared the ethanol:water solution (Table 3).  
The importance of vehicle effects on  sensitisation and elicitation in contact allergy is well known 
from animal studies in both guinea pigs (61) (62) and mice (the Local Lymph Node Assay)(63)). No 
simple relationship between allergen, vehicle and sensitization has been found (14;63;64) suggesting 
that allergens should be tested in vehicles as close as possible to the vehicle used in the product. Our 
results show how encapsulation of allergens in three different drug delivery systems relevant for 
pharmaceutical and cosmetic industry may affect the sensitizing potency in the Local Lymph Node 
Assay. The results show that no simple relationship exist between the drug delivery system and the 
sensitising capacity in the Local Lymph Node Assay exist, since e.g. ethosomes loaded with 
isoeugenol, dinitro-chloro-benzene or potassium dichromate increase or do not change the sensitising 
capacity in the Local Lymph Node Assay compared to a solution of the allergens without the 
ethosomes. It may be the unique combination of the allergen and the drug delivery system which 
causes the change in the sensitising properties and therefore each system should be evaluated on a case 
by case basis for risk assessment. Polycaprolactone loaded with lipophilic allergens (dinitro-chloro-
benzene and isoeugenol) showed reduced sensitisation in the Local Lymph Node Assay compared to 
acetone:olive oil and liposomes. This is in contrast to the suggestion in a case report (51). However, 
the Local Lymph Node Assay is a sensitisation experiment and the case report concerns elicitation. 
Further, we do not know the exact composition of the polycaprolactone in the cosmetic product. Octyl-
methoxycinnamate, a UV filter used in sunscreens, penetrate significant less when encapsulate in PCL 
compared to non-encapsulated octyl-methoxycinnamate (65). Potassium dichromate encapsulated in 
polycaprolactone did not alter the sensitizing capacity in the Local Lymph Node Assay compared to 
Potassium dichromate in water. This is somehow expected since hydrophilic chemicals do not bind to 
the lipid membrane or to the polycaprolactone but rather stay in the aqueous phase as seen from the 
encapsulation efficiencies inTable 6.  Therefore, the altered sensitisation capacity may not be caused 
by the lipid itself, but is more likely due to the encapsulation of the allergen in the lipid membrane. 
Isoeugenol formulated in acetone:olive oil was a significant stronger sensitizer compared to propylene 
glycol, which also is reported in the literature (14;66). We found approximately the same lymph node 
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proliferation as Ryan et al when testing potassium dichromate with a wetting enhancer (even though 
we used a polymer with a molecular weight of 4400 MW compared to Ryans’ pluronic L92 
(MW:3650))(15).  
Liposomes and polycaprolactone are formulated in an aqueous solution which makes it impossible to 
compare the effect of polycaprolactone and liposomes alone, since lipophilic allergens must be 
formulated in an organic control solution which would dissolve the liposomes and polycaprolactone 
particles. We have added a surfactant to the lipophilic allergens formulated in liposomes and 
polycaprolacone and compared it to the allergens formulated in an organic solution (acetone:olive oil, 
ethanol:water or propylene glycol). This difference should be kept in mind when results are 
interpreted. Reducing the size of liposomes did not alter the sensitizing capacity in the Local Lymph 
Node Assay but reducing the size of ethosomes did increase the sensitizing capacity. Diverging results 
are found in the literature of the relation between the size of liposomes and bioavailability of the 
encapsulated compound, but this might depend on the exact composition of the liposomes (67;68). 
 
Conclusion 
Formulating contact allergens in different microvesicular systems may alter their sensitizing 
properties. Ethosomes was able to enhance the sensitizing capacity of dinitro-chloro-benzene and 
isoeugenol and polycaprolactone protected the lipophilic allergens against sensitization. Diverging 
results where obtained on the size of vesicles. A case by case evaluation is recommended for the 
assessment of sensitising properties of product ingredients encapsulated in microvesicles.   
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7.2. Elicitation studies with isoeugenol and 
methyldibromoglutaronitrile (paper III) 
7.2.1. Results 
20 subjects participated in the methyldibromoglutaronitrile serial dilution patch test and eighteen in the 
Repeated Open Application Test . One subject had  negative patch tests and 8 subjects a negative 
Repeated Open Application Test and they were removed from further analysis.  
8 subjects participated in the isoeugenol serial dilution patch tests and the Repeated Open Application 
Test and all subjects had a positive patch test. Six subjects had a positive Repeated Open Application 
Test (one subject after 45 days) and two did not react during the exposure period. 
Isoeugenol and methyldibromoglutaronitrile formulated in ethosomes significantly enhanced the patch 
test reactions compared to the same allergens in ethanol:water, making ethosomes the only difference 
(Figure 13 and 14). However, when POPC was added to ethanol:water – without extrusion of vesicles 
– there was no difference in response to isoeugenol in ethosomes (Figure 15).  The Repeated Open 
Application Test did not show a significant difference for any of the allergens, but a trend towards a 
more rapid developing positive reaction was found for isoeugenol formulated in ethosomes compared 
to isoeugenol formulated in ethanol:water (Table 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
MICOVESICLE FORMULATIONS AND CONTACT ALLERGY – PH.D. THESIS BY JAKOB TORP MADSEN 
 
 45
Figure 13. 
Patch test results of methyldibromoglutaronitrile (MDBGN)(n=19) and isoeugenol (n=8) encapsulated in ethosomes 
(100mg/ml) compared to the same concentrations of allergen in ethanol:water. A significant increase in patch test response 
is seen for both allergens encapsulated in ethosomes (MDBGN, p<0.0001 and isoeugenol p<0.05). Increased allergen 
concentration also increased the elicitation response (MDBGN p<0.0001 and isoeugenol p<0.007)( two-way ANOVA). 
Results are expressed as means ± SEM. 
 
 
Figure 14.  
Result of a serial dilution patch test in a sensitised volunteer with methyldibromoglutaronitrile (MDBGN) using IQ 
chambers and 15µl test substance formulated in ethosomes and ethanol:water. 
 
Ethanol:water
0.63mg/ml MDBGN in ethanol:water
0.21mg/ml MDBGN in ethanol:water
0.10mg/ml MDBGN in ethanol:water
Ethosomes
0.63mg/ml MDBGN in ethosomes
0.21mg/ml MDBGN in ethosomes
0.10mg/ml MDBGN in ethosomes
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Characterisation of ethosomes 
Vesicle size measured before and after experiments remained stable in the test tubes for the duration of 
the experiment. All ethosomes were between 333±13 and 463±13 nm and polydispersity index ranged 
from 0.06±0.04 - 0.22±0.03, and can be regarded as monodisperse. The encapsulation efficiency of 
isoeugenol to ethosomes was 77.3±0.3% and for methyldibromoglutaronitrile 21.8±4.3%.  
 
7.2.2. Discussion 
Using a protocol with precise dosing and characterization of test preparations, it is for the first time 
shown that lipophilic contact allergens encapsulated in ethosomes can enhance the patch test reactions 
in sensitized individuals compared to the same allergens in control solution of 40 % ethanol in water 
without lipid vesicles. Other vehicle effects on both sensitization and elicitation responses have 
previously been reported in experiments using the Local Lymph Node Assay, guinea pigs, and human 
volunteers as test subjects (14;26). However, the effect of new encapsulating vehicles has not been 
Table 7. 
Repeated open application test performed with isoeugenol 
(n=6) and methyldibromoglutaronitrile (MDBGN) (n=10) 
formulated in ethosomes and ethanol:water as vehicles. 
Results are presented as mean days ± SEM to a positive 
reaction. No significant difference was observed (Wilcoxon 
Signed Rank Test) for both allergens even though a trend 
towards a faster developing reaction was seen by isoeugenol 
formulated in ethosomes compared to the ethanol:water 
formulation (p=0.31). 
 
Isoeugenol 
Ethosomes Ethanol:water 
D
ay
s 
to
 p
os
iti
ve
 
R
O
AT
±S
D
 
 
7.7±2.4 15.3±7.3 
Methyldibromoglutaronitrile 
Ethosomes Ethanol:water 
10.7±2.3 10.1±2.0 
 
Figure 15.  
Patch test results with 6.5 mg/ml isoeugenol 
formulated in ethosomes (300nm) and in 
POPC:ethanol:water (n=8). No significant 
difference was observed (Wilcoxon signed rank 
test). Results are expressed as means ± SEM. The 
picture shows the light scattering effect of small 
extruded vesicles of 300nm (left) versus non 
extruded vesicles (right). 
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studied before. No difference was seen when POPC was added to the ethanol:water solution compared 
to the ethosome formulation (Figure 15). A tentative explanation of the results is that spontaneous 
formation of vesicles occurs when POPC is mixed with water (or ethanol:water). However, the 
vesicles are not of homogeneous size and they are multilamellar compared to vesicles extruded 
through a filter of equal pore size which makes the vesicles more uniform and single lamellar. The 
light scattering effect of small extruded vesicles (300 nm) versus non extruded vesicles is clearly seen 
in Figure 15. Due to very high polydispersity indexes dynamic light scattering measurements were not 
applicable in the POPC:ethanol:water formulation.  
Repeated Oopen Application Test performed with methyldibromoglutaronitrile and isoeugenol with 
and without ethosomes showed no significant difference in lag time until a positive response, even 
though a trend towards a more rapid developing reaction occurred with encapsulated isoeugenol 
compared to isoeugenol in ethanol:water. We have no explanation for this discrepancy between patch 
test results and Repeated Open Application Test, but occlusion may play a role. It has been reported 
that occlusion decreases penetration of compounds through the skin when encapsulated in 
Transfersomes™ (43) but since there is no clear documented relation between skin penetration and the 
sensitizing capacity of an allergen (5;69), altered penetration is probably not the key to the different 
findings in our results. Further experiments are needed to clarify this problem. 
Increased patch test reactivity correlates with increased Repeated Open Application Test reactivity for 
some allergens as methyldibromoglutaronitrile and isoeugenol (19;70), but it is not always the case 
(71). Isoeugenol is less lipophilic and better retained inside the ethosomes compared to 
methyldibromoglutaronitrile as expressed by higher encapsulation efficiency (77% vs. 22%). Whether 
this difference accounts for the discrepancy between the Repeated Open Application Test and patch 
test reactions of methyldibromoglutaronitrile and isoeugenol encapsulated in ethosomes remains 
speculative, but obviously the low encapsulation efficiency of methyldibromoglutaronitrile is enough 
to produce significant changes in the test reactions if the encapsulation efficiency is an important 
parameter. A direct comparison is only valid for a single allergen when formulated in different 
vehicles and not between different allergens, since allergens with significantly different chemical 
structures and thereby physico-chemical properties (e.g. log P) will influence the vesicle properties 
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(e.g. stability, encapsulation efficiency and skin penetration) and subsequently complicate data 
discussion. 
 
The clinical implications of these results are so far uncertain. However, the cosmetic industry should 
consider the effect of encapsulation on a case by case basis because certain ingredients may become 
more allergenic when encapsulated.  Dermatologists investigating patients with allergic reactions to 
consumer products using encapsulation technology should consider the risk of false negative results, if 
testing with ingredients in conventional patch test vehicles. Testing with encapsulated ingredients 
should be performed when possible.   
7.3. Skin penetration properties and release kinetics (paper IV) 
7.3.1. Results 
Ethosome formulation of dinitro-chloro-benzene significantly increased the percutaneous absorption 
of dinitro-chloro-benzene compared to an ethanol:water formulation of dinitro-chloro-benzene (Figure 
16 and Table 8). In contrast, the percutaneous absorption of isoeugenol formulated in ethosomes was 
significantly reduced compared to an ethanol:water formulation of isoeugenol. dinitro-chloro-benzene 
formulated in ethosomes had a slightly (non significant) increased dermis deposition compared to the 
ethanol:water formulation, but no difference in epidermal deposition. On the contrary, the ethosome 
formulation significantly decreased the dermis deposition of isoeugenol and caused a more limited and 
non-significant increase in epidermal deposition of isoeugenol. The ethosome formulation caused a 
significantly increased relative skin deposition of isoeugenol, whereas the ethosomes had a more 
limited but opposite effect on the relative skin deposition of dinitro-chloro-benzene. A significantly 
increased lag-time was found for isoeugenol formulated in ethosomes compared to the ethanol:water 
formulation, whereas the lag-time of dinitro-chloro-benzene was not significantly affected by the 
ethosome formulation. The max flux as well as the permeability coefficient of isoeugenol was 
significantly lower, when isoeugenol was formulated with ethosomes compared to the ethanol:water 
formulation, whereas  no difference was seen for the dinitro-chloro-benzene formulations. In summary 
all parameters showed an opposite trend for the two allergens in ethosomes and ethanol:water.  This 
observation is a consequence of the decreased release rate when dinitro-chloro-benzene as well as 
isoeugenol was formulated in ethosomes (Figure 17 and Table 9). An interesting observation was that 
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the effect of ethosome formulation was evident at the lowest concentration of ethosomes applied for 
isoeugenol (30 mg/mL), whereas a three time’s higher concentration of ethosomes was required to 
decrease the release rate significantly for dinitro-chloro-benzene. No measureable adherence of 
dinitro-chloro-benzene or isoeugenol to glass,  protein binding, or  remaining test compounds in skin 
samples following the extraction procedures were observed. 
Size and encapsulation efficiencies show that ethosomes loaded with isoeugenol are slightly larger 
compared to dinitro-chloro-benzene loaded ethosomes (Table 10). Encapsulation efficiencies are of 
the same magnitude.  
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Figure 16.  
(A) shows a significant increased percutaneous absorption after 12 hours when dinitro-chloro-benzene (DNCB) is formulated in ethosomes compared to 
an ethanol:water formulation and (B) shows a significant decreased percutaneous absorption after 8 hours when isoeugenol is formulated in ethosomes 
compared to an ethanol:water formulation. (n=8, ** P<0.01, ***P<0.001, two-way ANOVA). Results are expressed as means ± SEM. 
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Table 8.  
Fraction of dinitro-chloro-benzene (DNCB) and isoeugenol retained in dermis and epidermis after 24 hours treatment of DNCB and isoeugenol formulated in ethanol:water or 
ethosomes using Franz diffusion cells. Furthermore, the max flux , lag-time and Kp are shown. Data are expressed as µg± standard deviation. (n=8, *p<0.05, **p<0.01, ***p<0.001) 
  
Epidermis 
deposition 
(µg/cm2) 
Dermis 
deposition 
(µg/cm2) 
Dermis/Epidermis 
ratio 
Total 
percutaneous 
absorption at 
24h/(µg/cm2) 
Total skin deposition 
in percent of total 
penetration
max flux 
(µg/cm2*h)) Lag-time(h) Kp/(µm/h) 
DNCB Ethanol:water 0.05±0.04 0.66±0.32 17.9±10.7 34±4 2.09±0,96 1.3±0,6 2.4±0,9 39±17 
Ethosomes 0.04±0.01 0.82±0.42 19.7±7.8 59±16*** 1.68±1,31 1.6±0,8 1.9±1,2 47±24 
          
Isoeugenol Ethanol:water 2.83±1.57 49±21 18.7±6.6 4635±1167 1.30±1.00 206±91 4.5±1.1 138±61 
Ethosomes 3.30±1.58 22±6** 8.7±5.9** 1327±443*** 2.05±0.55* 69±21* 6.8±1.4** 59±18* 
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Figure 17. 
Release time for dinitro-chloro-benzene (DNCB) and isoeugenol in an ethanol:water and in 3 concentrations of ethosomes 
evaluated by dialysis. Both allergens are released significantly slower when formulated in increasing ethosomes 
concentrations. Data represents mean±standard error of mean. (N=3, p< 0.0001 for DNCB and p<0.0025 for isoeugenol, 
two-way ANOVA). 
 
 
 
 
Table 9. 
Dialysis experiments show an increased T50% value with increasing 
amount of ethosomes in the sample of dinitro-chloro-benzene and 
isoeugenol formulated in increasing concentrations of ethosomes. 
Data represents means ±standard deviations. (N=3, *p<0.05, 
**p<0.01, ***p<0.001. One-Way ANOVA with Newmann-Keuls 
post hoc test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T 50% POPC (mg/ml) 
 0 30 60 90 
Dinitro-chloro-benzene 10±1 14±1 21±15 33±9 
Isoeugenol 10±1 32±6* 26±5** 44±8*** 
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Table 10.  
Overview of physical-chemical properties, size of ethosomes, skin penetration and release time formulated in ethosomes of 
isoeugenol and DNCB. * indicates experimental values obtained using the software: US EPA. [2010]. Estimation Programs 
Interface Suite™ for Microsoft® Windows, v 4.00]. United States Environmental Protection Agency, Washington, DC, 
USA. # Data represents mean ± standard deviations (N=3). 
 
 DNCB Isoeugenol 
Molecular weight  202.5 164.21 
Water solubility Insoluble  Slightly soluble 
Log P (O:W) 2.17* 3.04* 
Encapsulation efficiency in ethosomes % 90±0.3# 77±0.3# 
Release time when formulated in 
ethosomes compared to ethanol:water Increased Increased 
Skin penetration when formulated in 
ethosomes  compared to ethanol:water Increased Decreased 
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7.3.2. Discussion 
We found contradictory percutaneous absorption and penetration patterns when comparing dintro-
chloro-benzene and isoeugenol formulated in ethanol:water and ethosomes and hence 
penetration/absorption characteristics could not explain the increased sensitizing capacity of both 
allergens when formulated in ethosomes. A marked difference between dintro-chloro-benzene and 
isoeugenol is the water solubility, the latter being much more water soluble compared to dintro-chloro-
benzene. Further, isoeugenol has higher logP and lower encapsulation efficiency compared to dintro-
chloro-benzene but both allergens showed a sustained release when formulated in ethosomes (Table 
10). Despite these differences both allergens increases their sensitizing potential when formulated in 
ethosomes, suggesting that the sustained release might be an important parameter of the observed 
differences in sensitizing capacity. All previously published studies investigating ethosome 
formulations and skin penetration show an increased penetration/absorption of the encapsulated 
compound. For the first time it is now shown that an ethosome formulation of a compound 
(isoeugenol) inhibited the percutaneous penetration compared to a control formulation without the 
vesicles. Andersen et al. showed in 1985 that chlorocresol formulated in propylene glycol had a lower 
sensitization capacity compared to an acetone:olive oil formulation. Both formulations had the same 
bioavailability of chlorocresol in the skin after 24 hours but the authors did not distinguish between 
skin deposition and did not measure skin absorption (62). In 1996 Heylings et al investigated vehicle 
effects of dintro-chloro-benzene formulated in acetone and propylene glycol and skin absorption in the 
Local Lymph Node Assay (72). They found an increased sensitizing capacity which correlated with an 
increased flux from 2 hours and onwards when dintro-chloro-benzene was formulated in acetone 
compared to propylene glycol, the latter having lowest EC3% value. After 24 hours the total skin 
absorption was similar for the two formulations (17). Further, the percentage of the applied dose 
absorbed through the skin at 4 hours was substantially greater when dintro-chloro-benzene was 
administered in acetone (17). For both vehicles, similar amounts of dintro-chloro-benzene were found 
on top of the skin at 4 hours, but markedly less had penetrated into or beyond the skin when propylene 
glycol was used as the vehicle, suggesting that increased absorption at 4 hours may be more important 
than absorption profile after 24 hours.We found comparable flux’es from 2 to 8 hours for dintro-
chloro-benzene formulated in ethosomes and ethanol:water. Beyond 8 hours only a slight increase in 
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flux was seen for the ethosome formulation. On the contrary we found a significant decreased flux and 
lag-time when isoeugenol was formulated in ethosomes compared to ethanol:water resulting in a lower 
Kp.  
 
Pendlington et al studied the sensitizer hexyl cinnamic aldehyde (HCA) in four different vehicles (73) 
of which  three previously had been tested in the Local Lymph Node Assay (25) in an attempt to study 
the epidermal/dermal disposition of the allergen. The authors did, however, not correlate the skin 
deposition of HCA in the three vehicles to the EC3% values of HCA in the different vehicles. When 
correlating the sensitizing potency of HCA in the three vehicles (in order of increasing potency: AOO, 
PG and ethanol) and skin disposition of HCA, a consistent correlation was found between low EC3% 
value and high flux (0-6 hours) and high cumulative skin absorption, but not between low EC3% value 
and HCA deposition in stratum corneum, epidermis and dermis. This is largely consistent with 
Heylings findings that the flux is important but not with our findings.  
 
In conclusion, there is no simple relationship between bioavailability, skin absorption and sensitizing 
capacity of contactallergens in different formulations. It appears that the first hours of skin penetration 
is decisive for sensitization development, In this study we focussed on 24 hours data for the skin 
deposition. It would be interesting to study allergen skin deposition from 0-8 hours. Ethosome 
formulations may affect allergen concentration deeper in the epidermis or dermis within this spectrum 
of time. New visualization techniques like confocal and two-photon microscopy allow real-time non 
invasive measurements of the penetration of fluorescent allergens in the different skin departments 
over time (27) and would be a suitable method for such studies. The time points of interest regarding 
penetration behaviour of allergens may be the first hours after topical application. 
It has been stated that skin penetration/absorption of allergens is of only minor importance, foran 
extremely strong sensitizer like trimellitic anhydride with a logP value of -2.5 , because it would be 
considered too hydrophilic to penetrate readily (69). Vehicle effects have been studied extensively 
using the mouse Local Lymph Node Assay. No cases have been reported where a compound classified 
as a weak sensitizer in one vehicle was classified as a strong sensitizer in another vehicle (14;25;66). It 
has been suggested that the enhanced lymph node cell proliferative responses induced by dintro-
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chloro-benzene when applied in sodium lauryl sulphate may be due to increased numbers of dendritic 
cells reaching the lymph nodes (74).  Further, it has been postulated that the vehicle in which dintro-
chloro-benzene is delivered to the skin may influence cutaneous metabolism secondary to, or 
independent of, altered absorption kinetics (72). Presumably similar mechanisms could explain the 
consistent higher sensitising capacity found in the Local Lymph Node Assay when a lipophilic 
allergen is formulated in ethosomes compared to ethanol:water solution. The mechanisms of allergic 
contact allergy are complex and perhaps it is the unique combination of allergen and vehicle that 
determines the sensitizing and elicitation properties and not just the skin penetration/absorption 
characteristics of the allergen alone.  
Formulating dinitro-choloro-benzene and isoeugenol in ethosomes increased the release time of the 
allergens from the dialysis bag (Figure 17). It took more than 1 h before the released amount of 
allergen from the ethosome formulation reached the amount of ethanol:water formulation. The speed 
of release of allergen from the formulation is perhaps more important than the speed of penetration 
when comparing sensitization properties in different vehicles. However, the exact mechanism of how a 
vehicle influences the sensitizing properties remains uncertain. The present study on two different 
allergens suggests that skin penetration properties on a wider scale (not just amount but also kinetics) 
are important parameters in relation to understanding the allergenicity of chemicals in various 
vehicles. 
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8. Generel discussion – Dermatitis related to exposure to 
products containing micro vesicles. 
The thesis contributes to the risk assessment of modern vehicle systems used in cosmetic and 
pharmaceutical products concerning contact allergy. Micro and nano vesicular dermal delivery 
systems as well as other carrier molecules have not been subject to a rigorous risk assessment 
concerning the effect on contact allergy before. Only two case reports have raised the possibility of 
increased allergenicity by incorporation of a contact allergen in vesicular dermal drug delivery 
systems.. However, patch tests with and without the liposomal formulation of propyl gallate were not 
performed (55), and no comparable vehicle was used in the case report of retinyl palmitate 
incorporated in polycaprolactone micro particles (petrolatum vs. water containing polycaprolactone 
particles) (51), so proof is absent. 
 
It is important to emphasize that the selected allergens are only model allergens. It is unlikely that 
potassium dichromate encapsulated in liposomes should find its way into the market. On the other 
hand, the fragrance ingredient isoeugenol could very well be encapsulated in liposomes along with the 
preservative methyldibromoglutaronitrile added an active antiwrinkle compound like a vitamin A 
derivative.  
 
 
Sensitization and elicitation 
For the first time a systematic controlled study characterizing the effect of encapsulating allergens in 
topical drug delivery systems with reference to the sensitizing and elicitation capacity of contact 
allergy has been performed. Four different contact allergens with different physico-chemical and 
sensitizing properties were investigated. Increased sensitization response was found in the Local 
Lymph Node Assay when dinitro-chloro-benzene and isoeugenol were encapsulated in ethosomes 
compared to formulations without ethosomes (75). Challenge experiments in sensitized volunteer 
patients using ethosomes loaded with methyldibromoglutaronitrile or isoeugenol showed enhanced 
patch test response compared to challenge tests with the same allergens in an ethanol:water (4:6) 
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formulation making the lipid vesicles the only difference between formulations (76). More classical 
vehicle effects on both sensitization and elicitation responses have previously been reported in 
experiments using the Local Lymph Node Assay and human volunteers as test subjects (14;26). 
However, the effect of new encapsulating vehicles on product allergenicity has not been studied 
systematically until now. An important conclusion is that not all micro particle delivery systems 
increase the sensitising capacity in the Local Lymph Node Assay. Polycaprolactone showed reduced 
sensitization when the lipophilic allergens (dinitro-chloro-benzene and isoeugenol) were encapsulated 
and no effect when the hydrophilic potassium dichromate was formulated in polycaprolactone micro 
particles. We cannot make general conclusions based on present results, but a trend is that formulation 
of hydrophilic allergens in the tested dermal delivery systems does not change the sensitizing capacity. 
No patch tests were performed with a hydrophilic allergen. Hydrophilic allergens do not bind to the 
lipid membrane but lipophilic allergens do, as seen from the encapsulation efficiencies in Table 6. 
Therefore, encapsulation efficiency seems to be an important parameter in risk assessment of 
sensitization. 
Interpretation of the sensitising capacity of polycaprolactone and liposomes with encapsulated 
lipophilic allergens should be done with caution; because the compared vehicle is organic solution vs. 
the micro particles in water added 1% surfactant. An experiment comparing different concentrations of 
polycaprolactone and liposomes with the same amount of lipophilic allergen would give more accurate 
and detailed information of the impact of the delivery systems on the sensitization capacity. This 
would be an interesting study in the future. However, since the only difference between liposomes and 
ethosomes is ethanol, it would not be over interpretation to conclude, that liposomes also enhance the 
sensitizing and probably the elicitation capacity as well.  
 
Nanoparticles - Does size matters? 
The strict definition of nanotechnology deals with structures of the size of 100 nm or smaller. 
Unfortunately, conflicting definitions of nanotechnology and blurry distinctions between different 
scientific fields have complicated the area (77).  In the cosmetic and pharmaceutical industry many 
products may carry the name 'nanotechnology', even if it is not nanotechnology in the original 
meaning of the word. It is the change in physical, chemical and biological properties when downsizing 
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particles that are of importance. Different size limits have been proposed for the term nanotechnology; 
from <100nm to < 1000nm(77;78). The EU Parliament and the Council of Ministers have accepted the 
definitions of <100nm used in the Opinion on nanotechnology and cosmetics from the Scientific 
Committee on Consumer Products. When considering the importance of vesicle size on dermal 
penetration and bioavailability of the encapsulated substance conflicting results exist.  
Major parts of the particles in these experiments exceeded the 100 nm size limit for nanoparticles. 
However, particles larger than 100nm also may show size specific properties e.g. liposomes of 120nm 
penetrate human skin in greater extend compared to liposomes of 810nm (68). The results presented in 
Table 3 shows diverging results on the sensitizing capacity when reducing the sizes of vesicles. 
Liposomes of different sizes loaded with dinitro-chloro-benzene did not reveal a change in sensitizing 
capacity but smaller ethosomes did increase the sensitizing capacity compared to larger one. On the 
other hand, ethosomes of different sizes loaded with isoeugenol did not change the strength of patch 
test reaction in sensitized human volunteers. These conflicting results make it hard to conclude 
whether or not size is an important parameter of these encapsulating technologies when speaking 
about sensitization and elicitation. If particle size matters, it is probably of minor importance or it 
could be dependent on the combination of the specific particle and allergen.  
 
A limited number of studies have tried to elucidate a possible correlation between sensitization and 
percutaneous absorption/penetration of contact allergens.  Previous studies have shown that vehicle 
induced effects on the sensitizing capacity could be related to changes in the skin absorption or 
penetration of allergens (79-81). However, no clear correlation of dermal bioavailability, percutaneous 
absorption/penetration and sensitization has been found even though it seems reasonably that 
increased dermal penetration should result in increased sensitization due to better bioavailability of the 
allergens to the Langerhans cells. Ethosomes are in general believed to increase the bioavailability in 
the skin. The present results showed that even though the ethosome formulation of isoeugenol and 
dinitro-chloro-benzene increased the sensitizing capacity compared to control formulations, it could 
not be correlated to a change in percutaneous penetration or absorption pattern, since the two allergens 
showed opposite penetration behaviour. These findings correlate very well with Andersen’s results of 
chlorocresol, which found no relationship between sensitization and bioavailability (62). Heylings 
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conclude that an increased flux might be responsible for increased sensitization, but also here our 
studies showed opposite results from the two allergens (72).  
An interesting finding was that ethosome formulations also are capable of decreasing the skin 
deposition and percutaneous absorption, which has not been reported in the literature before.  
 
9. Conclusion 
The dermatotoxicologic risks from skin exposure to products using these carrier systems are 
considered low. No general rules can be concluded from the experiments presented and risk 
assessment should be done on a case by case basis.  Given the limited information available it is 
important that dermatologists are aware of the use of encapsulation technology in products causing 
contact dermatitis, because encapsulation of product ingredients may affect allergenicity in some 
cases.  It may be difficult to discover whether a product contains microvesicles if it is not mentioned 
on the label. Words like “nanosphere”, “liposome” and “encapsulated” can be looked for, but often not 
in the label but rather in the marketing folder. The website “www.nanotechproject.org ” registers 
consumer products using nanotechnology and different carrier technologies based on information from 
the manufacturers or other sources. The list is far from complete but can be helpful.  Dermatologists 
investigating patients with allergic reactions to consumer products using encapsulation technologies 
should consider the risk of false negative results, if testing with ingredients in conventional patch test 
vehicles. It is important to collaborate with the manufacturer. Sometimes they can provide the 
dermatologist with samples of encapsulated compounds for patch testing (51). If these new 
formulation systems really pose a risk for consumers regarding development of allergic skin reactions 
from use of topical products containing this technology, is so far not documented but experimental 
data shows that it is possible.  Dermatologists are incited to look for dermatitis patients with possible 
allergic skin reactions from topical products using nano- or microvesicle technologies, and be aware of 
the importance of patch test vehicle. 
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10. Future perspectives 
The increased use of vesicle systems in topical skin products requires a continuous search for possible 
dermatotoxicological side effects, e.g. enhanced skin penetration and development of cutaneous 
allergy to product ingredients encapsulated. The thesis focuses on few types of encapsulating vehicles. 
Other test designs are possible for investigating interaction between encapsulation technologies in 
animal and man. More dose response studies are needed . Further, new vehicle systems should be 
tested when they enter the market.  It is important that independent researchers in the field of contact 
allergy continue to investigate vehicle effects. Also clinical dermatologist should look for new 
possible vehicle effects when they do patch testing. 
It seems obvious that the degree of penetration of an allergen is an important parameter in the 
sensitizing and elicitation phases of contact allergy. Much works need to done here, since the few 
studies that exist show conflicting results. In order to investigate the penetration factor of sensitization, 
two-photon microscopy and confocal microscopy could be useful methods, since they allow for a non-
invasive measurement of fluorescent contact allergens like rhodamine B isothiocyanate, which makes 
it possible to follow the allergen over time when it penetrates the skin. These techniques also make it 
possible to show exactly what happens to the vesicular carrier systems and might answer following 
important questions:  For how long time is the vesicles intact? Do they break down into its constituents 
on the skin or does this happens deeper in the skin? Does the size of the vesicles play a role in the 
depth of penetration of the active compound? All these important questions may inspire for additional 
research projects. 
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Vesicular systems, such as liposomes and ethosomes, are 
used in cosmetic and pharmaceutical products to encap­
sulate ingredients to protect ingredients from degra­
dation, to increase bioavailability, and to improve cos­
metic performance. Some reports have suggested that 
formulation of cosmetic ingredients in vesicular carrier 
systems may increase their contact allergy elicitation 
potential in humans. However, no sensitization studies 
have been published. We formulated two model contact 
allergens (isoeugenol and dinitrochlorobenzene) in etho­
somes and investigated the sensitization response using 
a modified local lymph node assay (LLNA). The results 
were compared with those for the same allergens in si­
milar concentrations and vehicles without ethosomes. 
Both allergens encapsulated in 200–300 nm ethosomes 
showed increased sensitizing potency in the murine assay 
compared with the allergens in solution without ethoso­
mes. Empty ethosomes were non­sensitizing according to 
LLNA. The clinical implications are so far uncertain, but 
increased allergenicity from ethosome­encapsulated to­
pical product ingredients cannot be excluded. Key words: 
skin sensitization; contact dermatitis; liposomes; ethoso-
mes; local lymph node assay.
(Accepted February 23, 2010.)
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Liposomes and ethosomes are used in cosmetic products 
to increase delivery of certain ingredients to the skin 
with the purpose of enhancing an alleged effect and/or 
to protect the ingredients from degradation. Increased 
biological effects of topical drugs formulated in different 
kinds of liposomes have been reported; for example, acy-
clovir encapsulated in ethosomes demonstrated improved 
clinical efficacy in herpes simplex treatment compared 
with conventional formulation (1), and methotrexate 
encapsulated in niosomes showed increased clinical 
efficacy compared with placebo (2). Other promising 
clinical results have been obtained with liposome-en-
capsulated drugs in the treatment of acne, xerosis, atopic 
dermatitis, vitiligo, and superficial thrombophlebitis, and 
demonstrate the possibilities for liposome formulations in 
dermatology (1, 3–9). Whether encapsulation of chemi-
cals in liposomes and other vesicular systems affects the 
allergenicity of product ingredients is not documented. 
Few clinical reports raise this question. Propyl gallate 
incorporated in liposomes has been suggested to boost 
the allergic potential in 13 patients. However, patch tests 
with and without the liposomal formulation were not 
performed (10). Furthermore, a case report described 
a woman developing severe allergic contact dermatitis 
from an anti-wrinkle cream containing retinyl palmitate 
encapsulated in polycaprolactone (PCL) (11). PCL is 
a polymeric carrier system capable of encapsulating 
lipophilic and hydrophilic agents. Retinyl palmitate is 
a rare contact allergen, and diagnostic patch tests have 
revealed that the patient reacted more strongly to encap-
sulated retinyl palmitate than to retinyl palmitate in pet-
rolatum, even though the retinyl palmitate concentration 
was much lower in PCL compared with the petrolatum 
preparation. The size of the PCL particles was larger 
than 100 nm (11). 
Liposomes are spherical vesicles with membranes 
consisting of one (unilamellar) or more (oligolamellar, 
multilamellar) bilayers of polar lipids, e.g. phosphati-
dylcholine (POPC). Liposomes are able to encapsulate 
hydrophilic molecules in the aqueous core and incor-
porate lipophilic molecules in the lipid bilayer (Fig. 1). 
The skin penetration properties of liposomes depend on 
modifications in size and composition of the vesicles, 
e.g. by adding different chemicals into the bilayer, such 
as cholesterol, surfactants and ethanol (12). Vesicles con-
sisting of pure lipids are often referred to as “liposomes”, 
whereas they are called flexosomes or transfersomes when 
surfactants and/or cholesterol are added in the bilayer, and 
ethosomes when ethanol is added. Formulating certain 
chemicals in ethosomes may increase skin penetration 
compared with transfersomes, while liposomes are be-
lieved not to penetrate the stratum corneum (13–15). 
How these vesicles behave once applied to the skin is not 
known, but different scenarios have been proposed. The 
vesicles can act as drug carriers controlling release of 
the encapsulated agent, provide a localized depot on the 
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skin, or provide delivery to the skin appendages (hair 
and follicles and sweat glands). Some liposomes may 
possess more of the above-mentioned characteristics, 
depending on the constituents of the liposomes and the 
encapsulated compound (16). 
The level and degree of sensitization in experimental 
contact allergy depends on the potency of the allergen and 
the induction dose. Furthermore, the vehicle is of major 
importance, both in the sensitization and the elicitation 
phase, as documented previously (17, 18). No simple cor-
relation exists between the skin absorption of the allergen 
and the degree of sensitization and elicitation (17). 
The present study is based on the hypothesis that for-
mulation of contact allergens in drug delivery systems 
may affect the sensitizing potential. Ethosomes were 
selected as the carrier system because they contain 
ethanol, thus allowing research into lipophilic allergens 
in water/ethanol mixtures with and without the phospho-
lipids. According to previous studies with ethosomes 
loaded with lipophilic compounds, the lipophilic com-
pound is located both on/in the lipid bilayer as well as 
in the core (19).
A modified murine local lymph node assay (LLNA) 
was chosen as the sensitization test. The skin sensiti-
zation response is determined by measuring the cell 
proliferation in the draining lymph nodes as a function 
of concentration after topical application of test com-
pounds. Two potent model allergens (isoeugenol and 
dinitrochlorobenzene (DNCB)) were selected to test our 
hypothesis, as only limited amounts of allergen can be 
associated with the ethosomes.
METHODS
Sensitization experiments
The standard LLNA assay was modified by use of water-ethanol 
(6:4) as a vehicle for comparison between encapsulated and 
dissolved allergen, making the ethosomes the only difference 
between these two test materials. The lymph node cell prolife-
ration was determined for each animal and expressed as mean 
disintegrations per minute (dpm) (20). Female CBA/Ca mice 
purchased from Harlan (Horst, The Netherlands), 8 weeks 
old, were housed in cages with HEPA-filtered airflow under 
conventional conditions in light-, humidity- and temperature-
controlled rooms with ad lib food and water. The animals were 
allowed to acclimatize for one week prior to the study. The 
experiments were carried out in accordance with Danish and 
European animal welfare regulations and were licensed by the 
Danish Animal Experimentation Inspectorate.
Ethosome preparation
Ethosomes with isoeugenol (CAS No. 97-54-1) (Aldrich, 
Brøndby, Denmark) or dinitrochlorobenzene (DNCB) (CAS 
No. 97-00-7) (Sigma-Aldrich, Denmark) were prepared as 
described by Touitou (19). Briefly, POPC (1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine) (Avanti Polar Lipids, 
Alabaster, USA) was dissolved in 96% ethanol containing 
isoeugenol or DNCB, and MilliQ water was added slowly to a 
final concentration of 40% (v/v) ethanol under magnetic stir-
ring (700 rpm) at 30°C. The suspension was stirred for 5 min 
and then extruded 10 times through two polycarbonate filters 
with a pore size of 200 nm using a Lipex® Extruder (Northern 
Lipids Inc., Burnaby, Canada). 
To study the effect of ethosome formulation the following 
control solutions were prepared: dinitrochlorobenzene (DNCB) 
or isoeugenol was dissolved in ethanol, whereafter MilliQ 
water was added to a final concentration of 40% (v/v) ethanol. 
Furthermore, another experiment was performed with DNCB 
in ethanol/water (4:6) solution with POPC added to investi-
gate the effect of the lipid without subsequent extrusion of 
ethosomes. 
The concentration of isoeugenol and DNCB in experimental 
solutions was determined by high-performance liquid chro-
matography (HPLC). Allergen concentration was measured 
by HPLC to ensure the allergen concentration matched the 
ethosomal formulation (see figures). 
A further experiment was performed to investigate varying 
amounts of POPC in order to study the impact of ethosomal 
concentration by adding 20, 40 and 60 mg POPC to the same 
volume of isoeugenol-ethanol solution. The ethosome prepa-
ration was compared with a 4:6 ethanol/water solution made 
from the same batch of isoeugenol in ethanol. The concentra-
tion of isoeugenol was not measured by HPLC in the POPC 
dose-response experiment. The formulations were kept in the 
darkness at 5°C and all preparations were made on the same 
day or the day before the LLNA experiment.
Characterization of ethosomes
Hydrodynamic particle diameters and polydispersity index 
(PI) of ethosomes, which describes the size distribution of the 
Fig. 1. Model of isoeugenol (yellow) 
encapsulated in an ethosome. Left-
hand figure: schematic representation 
of a unilamellar liposome. Right-
hand figure: enlarged view from a 
coarse-grain computer simulation of 
phosphatidylcholine (POPC). The 
membrane patch represents a 45 × 50 
Å  area from the published coarse grain 
simulation data. The temperature was set 
to 20ºC. Since the solution contains 40% 
ethanol, an equilibrium of the lipophilic 
allergen isoeugenol is established 
between the POPC membrane and the 
inner and outer fluid.
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particles, were determined by dynamic light scattering (DLS) 
using a BI-200SM instrument from Brookhaven Instruments 
(Holtsville, USA). This incorporates a 632.8 nm HeNe laser 
operated at a fixed scattering angle of 90°. A 20 µl volume of 
ethosome-solution was diluted in 1.5 ml ethanol-MilliQ water 
(40%). The measurements were conducted in triplicate in a 
multimodal mode of 180 s. The size of ethosomes was measured 
on the day of preparation and directly after the experiment. 
Encapsulation efficiency
The encapsulation efficiency (EE%) of isoeugenol and DNCB 
by ethosomal vesicles was determined by ultracentrifugation, 
as described by Heeremans et al. (21), and later used on etho-
somal systems by Touitou et al. (19). Ethosomal preparations 
containing DNCB or isoeugenol were kept overnight at 5°C, 
whereafter they were spun at 40,000 rpm for 3 h in a Hitachi 
Sorvall Discovery 90SE ultracentrifuge with a swing-out 
rotor from Sorvall (Breda, The Netherlands) (SW50.1). The 
supernatant was removed immedi ately and drug quantity was 
determined in both the sediment and the supernatant. Binding 
efficiency was calculated as follows: [(T-C)/T]*100, where T 
is the total amount of chemical detected in both the supernatant 
and sediment, and C is the amount of chemical detected only in 
the supernatant. The procedure was performed in triplicate.
Quantification of isoeugenol and DNCB in ethosomes
HPLC analysis was conducted on an Ultimate 3000 series from 
Dionex® (Hvidovre, Denmark) with a diode array detector. A 
Dionex® RP-18 Acclaim 300 C18 reversed phase column was 
used. The temperature of the column and the sample rack in 
the autosampler was set to 20°C. Mobile phase: 75% methanol, 
25% MilliQ water; isocratic elution for 30 min; and flow rate 
of 1 ml/min. The separations were monitored at 270 nm. The 
injection volume was 10 µl. Pure reference compounds were 
used to make external calibration curves from which the con-
centrations of DNCB and isoeugenol were determined. 
Statistical data analysis
Results are expressed as means ± standard error of mean (SEM). 
Statistically significant differences in the isoeugenol and DNCB 
experiments were determined using one-way analysis of vari-
ance (ANOVA) and Student-Newman-Keuls test for post hoc 
analysis with p < 0.05 as a minimal level of significance. We 
used the statistical software package: graphpad Prism 4 from 
graphPad Software Inc (San Diego, CA, USA).
RESULTS
The LLNA experiments showed a significantly in-
creased sensitization from isoeugenol-loaded ethoso-
mes compared with isoeugenol dissolved in ethanol/
water (Fig. 2A). Isoeugenol concentration in all for-
mulations was 1.1% w/v. The experiment was repeated 
twice with equivalent results. A significantly increased 
sensitizing capacity was also found for ethosomes loa-
ded with DNCB (0.03% w/v)) compared with DNCB 
in the aqueous-ethanol solution and empty ethosomes 
(Fig. 2B). The dose of ethosomes was another important 
factor as there was a linear dose-response relationship 
between concentration of ethosomes and the sensiti-
zation obtained, reaching a significant level at 60 mg/
ml POPC (Fig. 3). The formation of ethosomes had 
a significant enhancing effect on sensitization with 
DNCB compared with DNCB in the ethanol/water/
POPC solution without extrusion (Fig. 4). 
Vesicle size measured before and after experiments 
remained stable for the duration of the experiment. All 
ethosomes were between 210 ± 8 and 317 ± 30 nm and 
polydispersity index ranged from 0.09 to 0.20 can be re-
garded as monodispersed. All batches showed an increase 
in PI of approximately 0.05 over the three experimental 
days. The encapsulation efficiency of isoeugenol into 
ethosomes was 24 ± 6% and into DNCB 18 ± 1%. 
DISCUSSION
These results indicate that contact allergens encap-
sulated in ethosomes can show enhanced sensitizing 
capacity compared with the same allergen concentra-
Fig. 2. Encapsulation of isoeugenol and dinitrochlorobenzene (DNCB) in ethosomes increases their sensitizing capacity. (A) Isoeugenol (1.1% w/v) loaded 
ethosomes (60 mg/ml) significantly increase the sensitizing capacity in the local lymph node assay compared with empty ethosomes and isoeugenol dissolved 
in ethanol/water (4:6). *p < 0.05 (n = 6 in each group). (B) DNCB (0.03 % w/v) loaded ethosomes (60 mg/ml) significantly increase the sensitizing capacity 
compared with DNCB in an ethanol/water solution (*p < 0.05) and compared with empty ethosomes (***p < 0.001). DNCB in ethanol/water (4:6) significantly 
increases the sensitizing capacity compared with empty ethosomes (**p < 0.01). Results are presented as mean ± standard error of the mean  of disintegrations 
per minute (dpm) per mouse (n = 6 in each group).
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tion in solution. Encapsulated isoeugenol in ethosomes 
showed repeatedly, significantly increased sensitization 
in a modified LLNA compared with isoeugenol in 
solution. Isoeugenol has previously been tested in the 
LLNA in different vehicles. The EC3 values (estimated 
concentration reduced to produce a stimulation index 
of 3) obtained were 0.9 (dimethylsulphoxide), 1.5 
(acetone/olive oil), 1.8 (water/ethanol 1:9), 2.5 (pro-
pylene glycol), and 4.9 (water/ethanol 1:1) (22). The 
dose of isoeugenol (1.1%) in the present experiments 
was selected due to limited solubility of isoeugenol 
in the ethanol/water solution. Higher concentrations 
were not possible due to instability of the ethosome 
formulation with change in vesicle size and PI. The 
isoeugenol concentration is thus below the EC3 values 
reported from other LLNA experiments with isoeugenol 
using ethanol/water as vehicle. In accordance with this, 
isoeugenol did not sensitize in the solution, only in the 
ethosome formulation. DNCB is a more potent allergen, 
which permitted a concentration above its EC3 value. 
DNCB 0.03% (w/v) showed stronger sensitization in 
the aqueous-ethanolic solution compared with empty 
ethosomes and the sensitization was further enhanced 
when formulated in ethosomes. However, the presence 
of POPC in the DNCB ethanol/water solution (0.04%) 
without extrusion of ethosomes also had an enhancing 
effect on sensitization (Fig. 4) compared with the etha-
nol/water solution. 
The vehicle effect on the sensitizing capacity differs 
between allergens, but the exact mechanism is unclear 
(18). Skin penetration appears not to be the major factor 
in the guinea pig maximization test (17) and the rela-
tionship between the percutaneous absorption and the 
extent to which sensitization is induced is still unclear 
in the LLNA, even though the rate of skin penetration 
appears to be important (23). 
Skin penetration properties of vesicular systems 
depend on physicochemical characteristics of the 
vesicles, and chemicals in vesicular systems may use 
varying pathways through the epidermis (24). In order 
for a contact allergen to sensitize an individual, close 
contact with dendritic cells is necessary, as would be 
expected to occur in damaged and eczematous skin, 
while penetration is less pronounced through normal 
skin. Hair follicles may represent a shunt that allows 
efficient and fast penetration through the skin barrier 
for encapsulated compounds (25–27). It has been sug-
gested that encapsulation of possible allergens protects 
against sensitization (28), but this was not the case in 
the present experiments. 
The term encapsulation or entrapment is often used 
in the literature, although true encapsulation probably 
occurs very little in these vesicular formulation sys-
tems, since they to some extent are dynamic systems 
that aim to obtain equilibrium between encapsulated 
and non-encapsulated compound (21). Therefore, the 
ethosome formulation contains encapsulated and non-
encapsulated compound. Furthermore, there appears 
to be a synergistic effect on enhancement of drug pe-
netration through the skin between non-entrapped and 
entrapped drug compared with entrapped drug alone 
(29). Heeremans et al. (21) stated that the term encap-
sulation or entrapment should be interpreted as binding 
or association of the chemical to the lipids. 
The size of the vesicle carriers may also be important, 
since decreasing liposomal size may increase the con-
centration of encapsulated substance in the skin (12). 
However, this was not studied here due to difficulties 
in producing stable ethosomes in different sizes. The 
conclusion of the present study is that formulation of 
chemicals in vesicular carrier systems can enhance 
the sensitizing capacity. This may be of particular 
importance for weaker allergens. Further research is 
Fig. 3. Encapsulated isoeugenol in ethosomes reaches a significant sensitizing 
potency by increasing the amount of phosphatidylcholine (POPC) to 60 mg/
ml ethosomes compared with the control vehicle (0 mg/ml POPC) in the local 
lymph node assay (LLNA). *p < 0.05 (n = 5 in each group) (Mean ± standard 
error of the mean).
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Fig. 4. Encapsulated dinitrochlorobenzene (DNCB) (0.04% w/v) in ethosomes 
increases the sensitizing capacity significantly (*p < 0.05, ***p < 0.001) 
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needed to clarify the clinical implications for topical 
drugs and cosmetics.
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1Introduction
Micro- and nanosized vesicles and different kinds of 
polymeric microparticles are used in topical products 
to encapsulate pharmaceutical and cosmetic ingre-
dients in order to improve their efficiency. Different 
lipid-based vesicular systems were developed with 
different properties depending on composition, for 
example, by adding ethanol or different surfactants into 
the bilayer (1,2). Vesicles consisting of pure lipids are 
often referred to as liposomes, whereas they are called 
ethosomes when ethanol is added, and flexosomes or 
transfersomes when surfactants and/or cholesterol are 
added in the bilayer, but this terminology is far from 
consistent. Changing the length of the lipid molecules 
and different coatings for the vesicles also changes their 
properties. Owing to the destabilizing effect of ethanol 
on lipid bilayers, it was thought that high concentra-
tions of ethanol were destructive to liposomal struc-
tures. However, the existence of vesicles as well as the 
ethosome structure was demonstrated by several tech-
niques including proton-decoupled nuclear magnetic 
resonance, transmission electron microscopy, and 
scanning electron microscopy, and the vesicles show 
a unimodal size distribution (3). Polymeric particles 
like polycaprolactone and solid–lipid nanoparticles are 
also capable of encapsulating chemical compounds for 
topical delivery to the skin and such products are on the 
market (4,5).
Increased treatment effects of topical products with 
encapsulated drugs have been reported in a clinical 
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Attempts to improve formulation of topical products are a continuing process and the development of micro- and 
nanovesicular systems as well as polymeric microparticles has led to marketing of topical drugs and cosmetics using 
these technologies. Encapsulation of some well-known contact allergens in ethanolic liposomes have been reported 
to enhance allergenicity compared with the allergens in similar vehicles without liposomes. The present report 
includes data on more sensitization studies using the mouse local lymph node assay with three contact allergens 
encapsulated in different dermal drug-delivery systems: liposomes, ethosomes, and polycaprolactone particles. 
The results show that the drug-delivery systems are not sensitizers in themselves. Encapsulating the hydrophilic 
contact allergen potassium dichromate in all three drug-delivery systems did not affect the sensitizing capacity of 
potassium dichromate compared with control solutions. However, encapsulating the lipophilic contact allergen 
dinitrochlorobenzene (DNCB) in polycaprolactone reduced the sensitizing capacity to 1211 ± 449 compared with 
liposomes (7602 ± 2658) and in acetone:olive oil (4:1) (5633 ± 666). The same trend was observed for encapsulating 
isoeugenol in polycaprolactone (1100 ± 406) compared with a formulation in acetone:olive oil (4491 ± 819) and in 
liposomes (3668 ± 950). Further, the size of DNCB-loaded liposomes did not affect the sensitizing properties. These 
results suggest that modern dermal drug-delivery systems may in some cases magnify or decrease the sensitizing 
capacity of the encapsulated contact allergen.
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trial for herpes simplex, psoriasis, acne, xerosis, atopic 
dermatitis, vitiligo, and superficial thrombophlebitis 
(6–13). The expected benefits of such formulations 
include improved bioavailability, protection of ingre-
dients from oxidization and photodegradation, and in 
some cases reduced skin irritancy (6). Further, a precise 
drug delivery to target cells may allow for a reduction of 
the concentration of an active ingredient as reported for 
5-aminolevulinic acid (5-ALA) formulated in 50 nm lipo-
somes for photodynamic therapy for treatment of acne. 
The liposomes concentrate in the pilosebaceous units 
thereby reducing the side effects, which open doors for 
new treatment modalities (14).
Encapsulation of contact allergens may also affect 
allergenicity as suggested in case reports (15,16). A 
woman developed severe allergic contact dermatitis 
from an anti-wrinkle cream containing retinyl palmitate 
encapsulated in polycaprolactone. Retinyl palmitate is a 
rare contact allergen, and diagnostic patch tests revealed 
that the patient reacted more strongly to encapsulated 
retinyl palmitate compared with retinyl palmitate in 
petrolatum, even though the retinyl palmitate concen-
tration was much lower when formulated in polycapro-
lactone compared with the petrolatum formulation 
(15). Polycaprolactone nanoparticles loaded with the 
lipophilic dying agent Nile Red have shown enhanced 
penetration of the molecule into the stratum corneum 
layers (up to 60 µm), compared with non-nanoparticle 
formulation (17).
Experimental studies using the mouse local lymph 
node assay (LLNA) for sensitization experiments 
showed that encapsulation of dinitrochlorobenzene 
(DNCB) and isoeugenol in ethosomes enhanced the 
sensitizing capacity compared with an ethanol:water 
(4:6 v/v) formulation (18). Volunteer patients showed 
in a clinical study that isoeugenol and methyldibromo-
glutaronitrile encapsulated in ethosomes significantly 
enhanced the patch test reactions in sensitized volun-
teers (19). The present report describes further LLNA 
studies with more allergens and other drug-delivery 
systems. This is important due to the lack of knowledge 
of sensitization properties for these new encapsulat-
ing technologies used increasingly in cosmetics and 
pharmaceutical products (20). Results from previ-
ously  published experiments are included in the result 
 figures (18).
Materials and methods
Two clinically important common contact allergens (the 
hydrophilic potassium dichromate and the lipophilic 
isoeugenol) were selected as model allergens due to their 
documented sensitizing properties, and in order to test a 
lipophilic and a hydrophilic allergen. Further, DNCB was 
included as an extreme experimental sensitizer because 
it limited how much allergen can be encapsulated in the 
drug-delivery systems.
Preparation of test solutions
Ethosomes
Ethosomes with encapsulated potassium dichromate 
were prepared as described by Touitou et al. (3). In brief, 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) (Avanti Polar Lipids, Alabaster, USA) was dis-
solved in 96% ethanol and Milli-Q water containing 
potassium dichromate (analytical grade; Alfa Aesar, 
London, UK, CAS 7778-50-9) was added slowly to a final 
concentration of 40% (v/v) ethanol under magnetic stir-
ring (700 rpm). The final concentration of the allergen 
was measured by high-performance liquid chromatog-
raphy (HPLC). In case of empty ethosomes for control 
measurements, water without potassium dichromate 
was added to the POPC/ethanol solution. The suspen-
sion was stirred for 5 min and then extruded 10 times 
through two polycarbonate filters with a pore size of 50, 
100, or 200 nm using a Lipex® Extruder (Northern Lipids 
Inc.). Empty ethosomes and an ethanol:water solution 
(4:6 v/v) of a corresponding concentration of allergen 
were used as control transport vehicles.
The isoeugenol (Aldrich, Denmark; CAS 97-54-1)- or 
DNCB (CAS 97-00-7; Sigma-Aldrich, Denmark)-loaded 
ethosomes were manufactured using the same tech-
niques with slight modifications. POPC was dissolved in 
96% ethanol containing isoeugenol or DNCB and Milli-Q 
water was added slowly to a final concentration of 40% 
(v/v) ethanol under magnetic stirring (700 rpm). In case 
of empty ethosomes for control measurements, ethanol 
without dissolved allergen was used.
Liposomes
Liposomes loaded with DNCB or isoeugenol were 
made by the thin film method (21). In brief, POPC and 
isoeugenol or DNCB were dissolved in chloroform and 
methanol (2:1 v/v) in a 250-mL round-bottomed flask. 
The mixture was evaporated in a rotary evaporator 
above the transition temperature of the phospholip-
ids to remove solvents under vacuum and producing a 
thin film in the flask consisting of POPC. The thin film 
was hydrated with Milli-Q water for 30 min. The vesicle 
suspension was extruded through a 50, 100, or 200 nm 
polycarbonate filter 10 times using the Lipex® Extruder to 
make a homogeneous size distribution of the vesicles. A 
non-extruded control solution containing larger vesicles 
of different sizes was also made for comparison. In man-
ufacturing potassium dichromate-loaded liposomes, the 
POPC was dissolved in chloroform and methanol (2:1 
v/v), solvents were evaporated under reduced pressure 
and afterward hydrated with Milli-Q water containing 
potassium dichromate, and the solution was extruded 
through a filter as described above. Allergen concentra-
tion was determined by HPLC.
Polycaprolactone microparticles
Polycaprolactone particles loaded with DNCB or 
isoeugenol were manufactured based on the solvent dis-
placement process (22). In brief, polycaprolactone (CAS 
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2498-41-4; Aldrich, Denmark) and a lipophilic allergen 
(DNCB or isoeugenol) were dissolved in 125 mL acetone 
at 45°C, and this organic phase was injected into 125 mL 
Milli-Q water containing 0.17 g Pluronic F-68™ (CAS 
9003-11-6; Aldrich, Denmark) in a round-bottomed flask 
under magnetic stirring (1200 rpm) at room temperature. 
Acetone and the aqueous phase were reduced to 5 mL 
under reduced pressure. Allergen concentration was 
measured by HPLC. All formulations were kept at 5°C. 
In case of empty polycaprolactone particles, no allergen 
was dissolved in the organic phase, but otherwise the 
same procedures were followed.
In case of potassium dichromate-loaded poly-
caprolactone particles, the polymer was dissolved in 
the organic phase and injected into an aqueous phase 
containing potassium dichromate and Pluronic F-68™. 
Otherwise, the same procedures as described above 
were followed.
To ensure sufficient contact with the skin in the LLNA, 
a surfactant (polyethylene glycol–polypropylene glycol, 
CAS 9003-11-6; Aldrich, Denmark) was added to lipo-
somes and polycaprolactone particle batches to a final 
concentration of 1% (v/v) immediately before each LLNA 
experiment.
To document vesicle size, stability, and encapsulation 
efficiency (EE), the following methods were used.
Dynamic light scattering Hydrodynamic particle diam-
eters and polydispersity index (PI) of ethosomes were 
determined by dynamic light scattering (DLS) using a 
BI-200SM from Brookhaven Instruments. This incorpo-
rates a 632.8 nm HeNe laser operated at a fixed scattering 
angle of 90°. A sample of 10 µL was diluted in 1190 µL 
40% ethanol:Milli-Q water mixture or pure Milli-Q water 
dependent of the original vehicle. The authors are aware 
that the dilution may change the microstructure of the 
vesicles, but the dilution was necessary to allow for suf-
ficient amount of light to pass the test solution. The mea-
surements were conducted in triplicate, in a multimodal 
mode of 120 sec. The size of particles was measured 
before and after the LLNA experiment.
Encapsulation efficiency The EE% of allergens formu-
lated in polycaprolactone, ethosomes, and liposomes 
was determined by ultracentrifugation as described 
by Heeremans et al. (23). Ethosomal, polycaprolac-
tone, and liposomal preparations containing DNCB, 
isoeugenol, or potassium dichromate were kept 12 h 
at 5°C and thereafter spun at 80.640 g for 3 h in an 
Hitachi Sorvall Discovery 90SE ultracentrifuge with a 
swing-out rotor from Sorvall (SW50.1). The superna-
tant was immediately removed and drug quantity was 
determined in both the sediment and the supernatant. 
Binding efficiency was calculated as follows: [(T−C)/T] 
x 100, where T is the total amount of chemical detected 
in both the supernatant and sediment, and C is the 
amount of chemical detected only in the supernatant. 
The procedure was done in triplicates.
Quantification of isoeugenol, DNCB, and potassium dichro-
mate HPLC analysis was conducted on an ultimate 
3000 series from DIONEX™ with a diode array detector. 
A DIONEX Acclaim® Surfactant column was used to sep-
arate isoeugenol and DNCB. Potassium dichromate was 
separated using a DIONEX Acclaim® 300 C18 column. 
The temperature of the column and the sample rack in 
the thermostated autosampler was set to 20°C. Mobile 
phase used for DNCB and isoeugenol: 75% methanol, 
25% Milli-Q water; isocratic elution for 30 min; and flow 
rate of 1 mL/min. The separations were monitored at 
270 nm. Mobile phase used for potassium dichromate 
consisted of 20% methanol for 10 min followed by a lin-
ear gradient of 90% methanol performed over 5 min, fol-
lowed by 40 min of 100% methanol to wash the column 
and 5 min of 20% methanol to equilibrate the column for 
the next run. Potassium dichromate was monitored at 
260 nm. Pure reference compounds were used to make 
external calibration curves from which the concentra-
tions of allergen were determined.
Sensitization experiments The LLNA was performed 
according to standard procedure (24) with the exception 
that the lymph node cell proliferation was determined 
for each animal and expressed as mean disintegrations 
per minute (dpm). The scintillation count data for each 
group were analyzed statistically. No EC3 values were 
calculated. Female CBA/Ca mice purchased from Harlan 
(the Netherlands), 8 weeks of age, were housed in cages 
with hepa-filtered airflow under conventional conditions 
in light-,  humidity-, and temperature-controlled rooms 
with food and water ad libitum. Test substances were 
applied on the dorsum of both ears of each mouse for 
three consecutive days. On Day 5, [methyl-3H]-thymidine 
was injected in the tail vein and after 5 h the mice were 
sacrificed and the draining lymph nodes were removed. 
A single cell suspension from each mouse was made and 
after two washing procedures with phosphate-buffered 
saline, the DNA was precipitated with trichloroacetic acid 
for 18 h and the thymidine incorporation was measured 
using β-scintillation counting. The standard vehicle in 
the LLNA is acetone:olive oil (4:1 v/v), which dissolves 
polycaprolactone, ethosomes, and liposomes. Therefore, 
we modified the LLNA by using either water:ethanol (6:4 
v/v) as control vehicle for ethosomes or water-added 
1% surfactant as control vehicle for liposome and poly-
caprolactone batches loaded with hydrophilic allergens 
making the drug-delivery system the only difference 
between batches. Lipophilic allergens were dissolved in 
ethanol:water (4:6 v/v), propylene glycol (PG, analytical 
grade, CAS 57-55-6; Riedel-de Haën, Seelze, Germany) 
or acetone:olive oil (acetone, analytical grade purchased 
from Aldrich, Denmark, CAS 67-64-1 and olive oil pur-
chased from Fluka, Denmark, CAS 8001-25-0) making the 
comparison with the drug-delivery systems less compara-
ble. The experiments were in accordance with Danish and 
European animal welfare regulations and were licensed 
by the Danish Animal Experimentation Inspectorate.
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Statistical data analysis
Results are expressed as mean ± standard deviation. 
Statistically significant differences in the experiments 
were determined using one-way ANOVA and Student-
Newman-Keuls test for post hoc analysis with P < 0.05 as 
a minimal level of significance.
Results
Empty ethosomes, liposomes, polycaprolactone parti-
cles, and the surfactants were not sensitizers themselves 
in the LLNA (Figures 1–3 and Table 1).
Ethosomes, liposomes, and polycaprolactone vesicles 
encapsulated with potassium dichromate showed no sig-
nificant effect on the sensitizing capacity compared with 
potassium dichromate in ethanol:water or Milli-Q water 
with 1% surfactant added (Figure 1).
The lipophilic contact allergens DNCB encapsulated 
in polycaprolactone reduced the sensitizing capacity to 
1211 ± 449 dpm compared with DNCB encapsulated in 
liposomes (7602 ± 2658 dpm) and DNCB formulated in 
acetone:olive oil (5633 ± 666 dpm) (Figure 2). The same 
trend was observed when encapsulating isoeugenol 
in polycaprolactone (1100 ± 406 dpm) compared with 
isoeugenol in acetone:olive oil (449 1 ± 819) and in lipo-
somes (3668 ± 950) (Figure 3). In contrast, isoeugenol 
(2343 ± 533 dpm vs 641 ± 349 dpm) and DNCB (2151 ± 925 
dpm vs. 1349 ± 443 dpm) in ethosomes showed a 
significant increased sensitizing capacity compared with 
formulations without ethosomes (Figures 2 and 3) (18). 
It is noteworthy from Figures 2 and 3 that liposomes gave 
higher sensitization responses than PG and polycapro-
lactone particles.
The size of DNCB-loaded liposomes (50, 100, 200 nm, 
and non-extruded) did not affect their sensitizing capac-
ity (Figure 2).
The surfactant was not a sensitizer itself but the sen-
sitizing capacity of potassium dichromate increased by a 
factor of 2 (from 7372 to 15737 dpm) when doubling the 
surfactant concentration (Table 1).
The size of the particles ranged from 65 to 2466 nm 
in case of liposomes, 245 to 436 nm for the ethosomes, 
and 231 to 343 nm for the polycaprolactone particles 
(Table 2). The sizes of the particles were stable dur-
ing the study and the PI was below 0.17, which can be 
regarded as monodisperse (except for the non-extruded 
liposomes). Every DLS measurement resulted in a uni-
modal size distribution curve. Encapsulation efficien-
cies of the hydrophilic potassium dichromate range 
from 0.7% in polycaprolactone to 16% in ethosomes 
as shown in Table 2. The lipophilic allergens (DNCB 
and isoeugenol) showed increased encapsulation effi-
ciencies compared with the hydrophilic potassium 
dichromate, with liposomes being the best to retain the 
allergens (92% for DNCB and 98% for isoeugenol) com-
pared with polycaprolactone (83% for DNCB and 84% 
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for isoeugenol) and ethosomes (90% for DNCB and 77% 
for isoeugenol).
The size of liposomes, ethosomes, and polycaprolac-
tone was stable during the time of experiment (3 days). 
The size of liposomes and polycaprolactone particles was 
stable for at least 22 days after adding 1% surfactant to 
the formulations (data not shown). Adding the surfactant 
to the polycaprolactone or the liposomal formulation did 
not produce a bi- or multimodal size distribution com-
pared with the liposomal and polycaprolactone formula-
tion alone.
Discussion
The importance of vehicle effects on sensitization and 
elicitation in contact allergy is well-known from animal 
studies in both guinea pigs (25) and mice (26). There is 
no simple relationship between type of contact allergen, 
type of vehicle, and sensitization properties (26–28). 
These results show that encapsulation of contact aller-
gens in three different drug-delivery systems relevant 
for the pharmaceutical and cosmetic industry may affect 
the sensitizing potency in the LLNA. The results confirm 
that there is no simple relationship between the drug-
delivery system and the sensitizing potency in the LLNA. 
The different encapsulation efficiencies of the allergens 
in the three drug-delivery systems may partly explain the 
change in sensitizing capacity. For instance, potassium 
dichromate showed very low encapsulation efficiencies 
in liposomes, ethosomes, and polycaprolactone, and no 
change in sensitizing capacity was seen when potassium 
dichromate was encapsulated in the three different drug-
delivery systems. This is somehow expected since hydro-
philic chemicals do not bind to the lipid membrane or 
to the polycaprolactone but rather stay in the aqueous 
phase as seen from the encapsulation efficiencies in 
Table 2. Therefore, the altered sensitization capacity may 
not be caused by the lipid itself but is more likely due to 
the encapsulation of the allergen in the lipid membrane. 
High EE may be an important parameter for effect on 
sensitization properties. The direction of the effect may 
depend on the specific combination of chemical and 
drug-delivery system, that is, DNCB and isoeugenol both 
showed high encapsulation efficiencies and a decreased 
sensitization capacity when encapsulated in polycapro-
lactone, and increased sensitization when encapsulated 
in ethosomes. The mechanism of action is not elucidated. 
When vesicle formulations or polymeric microparticles 
dry down on skin, their microstructure may change and 
therefore the characterization of their structure are only 
valid before applying them on the skin. To the authors’ 
knowledge, no publication state that intact vesicles exist 
when they get in contact with the skin. Polycaprolactone 
loaded with lipophilic allergens (DNCB and isoeugenol) 
showed reduced sensitization in the LLNA compared 
with acetone:olive oil and liposomes. This is in contrast 
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to the suggestion in a case report (15). However, the 
LLNA is a sensitization experiment and the case report 
concerns elicitation. Further, we do not know the exact 
composition of the polycaprolactone in the cosmetic 
product. Octyl methoxycinnamate (OMC), a UV filter 
used in sunscreens, penetrates significantly less when 
encapsulated in polycaprolactone compared with non-
encapsulated OMC (29) but other studies showed the 
opposite (17). Isoeugenol formulated in acetone:olive 
oil was a significantly stronger sensitizer compared with 
PG, which is also reported in the literature (28,30). We 
found approximately the same lymph node proliferation 
as Ryan et al. (31) when testing potassium dichromate 
with a surfactant (even though we used a polymer with 
a molecular weight of 4400 MW compared with Ryan 
et al.’s pluronic L92 (MW 3650).
Liposomes and polycaprolactone are formulated in an 
aqueous solution, which makes it impossible to compare 
the effect of polycaprolactone and liposomes alone, since 
lipophilic allergens formulated in an organic solution 
would dissolve the liposomes and polycaprolactone par-
ticles. We added a surfactant to the liposome and poly-
caprolactone formulations with lipophilic allergen and 
compared sensitization response to the allergens dissolved 
in organic solutions (acetone:olive oil, ethanol:water, or 
PG). These minor variations in formulations should be 
kept in mind when results are interpreted. Changing the 
size of liposomes did not affect the sensitizing capacity in 
the LLNA. Diverging results are reported on the relation-
ship between the size of liposomes and bioavailability of 
the encapsulated compound, and this will also be affected 
by the composition of the liposomes (1,32).
The surfactant may be able to coalesce into ves-
icles spontaneously, but this was not found in our 
experiments.
Conclusion
Formulating contact allergens in different microvesicles 
and polymeric microparticles may affect their sensitiz-
ing properties. Ethosomes were able to enhance the 
Table 1. Adding a surfactant to potassium dichromate dissolved 
in water increases the sensitizing capacity in the local lymph 
node assay.
Sample description
Potassium  
dichromate (%w/v)
Lymphocyte 
proliferation 
(mean DPM)
Surfactant 2% (n = 4) 0.0 855
Surfactant 1% (n = 4) 0.5 1843
Surfactant 1% + (n = 4) 1.0 4019
Surfactant 2% + (n = 4) 0.5 3934
Lymph nodes were pooled for each group and each result is 
expressed as disintegrations per minute (DPM) per mouse.
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sensitizing capacity of DNCB and isoeugenol and poly-
caprolactone protected the lipophilic allergens against 
sensitization.
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CONTACT DERMATITIS
Ethosome formulation of contact allergens may
enhance patch test reactions in patients∗
Jakob Torp Madsen1, Stefan Vogel2, Ann-Therese Karlberg3, Carl Simonsson3, Jeanne Duus Johansen4 and
Klaus E. Andersen1
1National Allergy Research Centre, Department of Dermatology and Allergy Centre, Odense University Hospital,
University of Southern Denmark, 5000 Odense, Denmark, 2Department of Physics and Chemistry, University of Southern
Denmark, 5000 Odense, Denmark, 3Dermatochemistry and Skin Allergy, Department of Chemistry, University of
Gothenburg, Go¨teborg, Sweden, and 4National Allergy Research Centre, Department of Dermato-allergology, Copenhagen
University Hospital, Hellerup, Denmark
Background: Ethosomes and liposomes are ultra-small vesicles capable of encapsulating drugs and
cosmetic ingredients for topical use, thereby potentially increasing bioavailability and clinical efficacy.
So far, few reports have suggested that formulation of cosmetic ingredients in vesicular carrier systems
may increase the allergenicity potential.
Objectives: To investigate the effect of ethosome formulation of isoeugenol and methyldibromo
glutaronitrile on the elicitation response under patch test conditions and by repeated open applications.
Patients/Materials/Methods: A total of 27 volunteer patients with a previous positive patch test reaction
to either isoeugenol or methyldibromo glutaronitrile were included in the study. In all patients, a serial
dilution patch test was performed with the allergen in question formulated in ethosomes and in an
ethanol/water solution. In addition, a repeated open application test (ROAT) was performed in a subset
of 16 patients, and lag time until a positive response was recorded.
Results: Both contact allergens encapsulated in ethosomes showed significantly enhanced patch test
reactions as compared with the allergen preparation in ethanol/water without ethosomes. No significant
difference in the median lag time was recorded between preparations in the ROAT.
Conclusions: Encapsulating potential contact allergens in ethosomes may increase the challenge response
as compared with the same concentrations in an ethanol/water base without ethosomes.
Key words: contact dermatitis; encapsulation; ethosome; liposome; patch test; repeated open application
test. © John Wiley & Sons A/S, 2010.
Conflicts of interest: The authors have no conflicts of interest.
Accepted for publication 12 June 2010
Ethosomes (ethanolic liposomes) and other carrier
systems for delivery of drugs and cosmetic ingre-
dients to and through the skin have been of much
interest, and show potential for use in clinical appli-
cations. Increased biological effects of encapsulated
drugs have been reported in clinical trials for her-
pes simplex, psoriasis, acne, xerosis, atopic dermati-
tis, vitiligo, and superficial thrombophlebitis (1–7).
*This work was financially supported by the Danish
Environmental Agency and the Aage Bang Foundation.
Suggested explanations for these intriguing effects
of encapsulated compounds as compared with con-
ventional formulations include improved bioavail-
ability, protection of encapsulated ingredients from
degradation and photo-oxidation, and reduced irri-
tancy.
We have recently shown that the sensitizing
capacity in the local lymph node assay (LLNA)
can be enhanced, as compared with conventional
formulations, by encapsulating dinitrochlorobenzene
and isoeugenol in ethosomes (8). The effect of
210 MADSEN ET AL. Contact Dermatitis 2010: 63: 209–214
encapsulation on the challenge phase in sensitized
humans has not been investigated, although a few
clinical reports have raised this issue. Propyl gal-
late incorporated in liposomes was suggested to
boost the allergic potential in 13 patients; however,
patch tests with and without the liposomal formu-
lation were not performed (9). Furthermore, a case
report described a woman developing severe aller-
gic contact dermatitis from an ‘anti-wrinkle’ cream
containing retinyl palmitate encapsulated in poly-
caprolactone (10).
The present study is based on the hypothesis that
formulation of contact allergens in vesicular drug
delivery systems may enhance the patch reaction
as compared with allergen formulations in conven-
tional vehicles. Ethosomes were selected as carriers
because they contain ethanol, allowing experiments
with lipophilic allergens in water/ethanol mixtures
with and without the phospholipids, and because
they have previously been shown to enhance the
sensitizing capacity of allergens in the LLNA (8).
Isoeugenol and methyldibromo glutaronitrile
(MDBGN) were selected as model allergens,
and formulated in ethosomes and ethanol/water
for performance of patch tests and repeated open
application test (ROATs) on human volunteers
with a previous positive patch test reaction to the
allergens.
Materials and Methods
Test subjects
The inclusion criteria were: age over 18 years, and
a previous positive patch test reaction to MDBGN
or isoeugenol within the last 10 years at the Depart-
ment of Dermatology, Odense University Hospital,
University of Southern Denmark. Exclusion cri-
teria were: active eczema on test sites, not being
able to cooperate for the ROAT, pregnancy, and
breast-feeding.
Forty-eight persons with a previous positive patch
test reaction to isoeugenol and 89 persons with a
previous positive patch test reaction to MDBGN
were invited to participate.
Study design
Three concentrations of MDBGN and two con-
centrations of isoeugenol formulated in ethosomes
and ethanol/water and blank controls were tested.
ROATs were performed with one concentration of
allergen formulated in ethosomes and ethanol/water.
The placement of the test concentrations and
vehicles in both tests were randomized and blinded
for the investigator and the subjects. After termi-
nation of the study, the randomization code was
broken. The study was performed according to the
Helsinki II declaration, and approved by the local
ethics committee (Southern Region of Denmark,
S-20090022).
Patch test
The patch tests were applied on IQ-chambers
(Chemotechnique® Diagnostics, Vellinge, Sweden),
and occluded for 2 days; the reactions were read
on D3. The reading scale developed by Fischer
et al. (11) was chosen, in order to detect smaller
differences in the allergic responses. The scale
was as follows: 0 = no reaction;1 = few papules
with no erythema and no infiltration; 2 = faint
erythema with no infiltration or papules; 3 = faint
erythema with few papules and no homogeneous
infiltration; 4 = erythema with homogeneous infil-
tration; 5 = erythema with infiltration and a few
papules; 6 = erythema with infiltration and papules;
7 = erythema with infiltration, papules, and a few
vesicles; and 8 = intensive erythema with infiltra-
tion and vesicles. J.T.M. performed all readings.
ROAT
Two 3 × 3 cm areas on the volar aspects of both
forearms were used. Twenty microlitres of test
preparation were applied two (MDBGN) or three
(isoeugenol) times daily, with a micropipette (Acura
815, 20 μl; Buch & Holm A/S, Herlev, Denmark)
with a fixed volume. Test subjects received two
marked bottles, each mark referring to a test area.
The solutions were spread on the area with the
tip of the pipette, and allowed to dry by evapora-
tion. The subjects received written instructions, and
were instructed orally and manually in using the
pipette. The dose of one application was 5.66 mg/ml
isoeugenol or 0.10 mg/ml MDBGN. When an area
showed a positive reaction (verified by the inves-
tigator), the subjects stopped application on that
test area and continued on the other area. A reac-
tion was defined as positive when 70% of the area
had erythema, papules, or vesicles. Numbers of
days until positive reactions occurred were counted.
J.T.M. performed the readings. If no ROAT reaction
developed within 4 weeks, application was stopped
(except in one case: here, the ROAT result on one
arm was positive after 18 days, and that on the other
after 45 days).
Ethosome preparation. Ethosomes with isoeugenol
(CAS no. 97-54-1; Aldrich, Brøndby, Denmark)
or MDBGN (CAS no. 35691-65-7; Alfa-Aesar,
Karlsruhe, Germany) were prepared as described
by Touitou (12). Briefly, 100 mg/ml 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC)
(Avanti Polar Lipids, Alabaster, AL, USA) was
dissolved in 96% ethanol containing isoeugenol
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or MDBGN, and MilliQ water was added slowly
to a final concentration of 40% (v/v) ethanol in
water The suspension was stirred for 5 min and
then extruded 10 times through two polycarbonate
filters with a pore size of 100 nm, using a Lipex®
Extruder (Northern Lipids, Burnaby, Canada).
The effect of the ethosomes was compared with
the following control formulations. MDBGN or
isoeugenol was dissolved in ethanol, and MilliQ
water was then added to a final concentration of
40% (vol/vol) ethanol in water. An extra experiment
was performed with isoeugenol in an ethanol/water
(4:6) solution with POPC (100 mg/ml) added to
investigate the effect of the lipid without subsequent
extrusion of ethosomes.
The concentrations of isoeugenol and MDBGN
were determined by high-performance liquid chro-
matography (HPLC), to ensure that the allergen
concentration of the control solution matched the
allergen concentrations in the ethosomal formula-
tions. All formulations were kept in darkness at
5◦C, and all preparations were made no more than
5 days prior to beginning the patch testing and
ROAT. Volunteers were instructed to keep the test
material for the ROAT in the refrigerator.
The final concentrations of isoeugenol were:
0.0, 2.80 and 6.54 mg/ml for the patch test, and
5.66 mg/ml for the ROAT. The final concentrations
of MDBGN were 0.00, 0.10, 0.21 and 0.63 mg/ml
for the patch test experiment, and 0.10 mg/ml for
the ROAT.
Characterization of ethosomes. Hydrodynamic par-
ticle diameters and the polydispersity index (PI)
of ethosomes, which describes the size distribu-
tion of the particles, were determined by dynamic
light scattering (DLS), using a BI-200SM instru-
ment from Brookhaven Instruments (Holtsville,
NY, USA). This incorporates a 632.8-nm HeNe
laser operated at a fixed scattering angle of 90◦.
Twenty microlitres of ethosome solution was
diluted in 1.5 ml of ethanol/MilliQ water (40%).
The measurements were conducted in triplicate in
a multimodal mode of 180 seconds.
Encapsulation efficiency. The efficiency of encap-
sulation (EE%) of isoeugenol and MDBGN by
ethosomal vesicles was determined by ultracen-
trifugation, as described by Heeremans et al. (13)
and later used on ethosomal systems by Touitou
et al. (12). Ethosomal preparations containing
MDBGN or isoeugenol were kept overnight at 5◦C,
after which they were spun at 143 360 g rpm for
3 hrs in a Hitachi Sorvall Discovery 90SE ultra-
centrifuge with a swingout rotor (SW50.1; Sorvall,
Breda, The Netherlands). The supernatant was
immediately removed, and drug quantity was deter-
mined in both the sediment and the supernatant.
Binding efficiency was calculated as follows:
[(T - C)/T ] × 100, where T is the total amount of
chemical detected in both the supernatant and sedi-
ment, and C is the amount of chemical detected only
in the supernatant. The procedure was performed in
triplicate.
Quantification of isoeugenol and MDBGN in
ethosomes. HPLC analysis of isoeugenol was con-
ducted on an Ultimate 3000 series from DIONEX™
(Hvidovre, Denmark) with a diode array detector. A
DIONEX® Acclaim®Surfactant column was used
for separation of isoeugenol. The temperature of the
column and the sample rack in the autosampler was
set to 20◦C. The conditions were as follows: mobile
phase, 75% methanol/25% MilliQ water; isocratic
elution for 30 min; and flow rate, 1 ml/min. The
separations were monitored at 270 nm. The injec-
tion volume was 10 μl. Pure reference compounds
were used to make external calibration curves,
from which the concentrations of isoeugenol were
determined. MDBGN is not UV-active, and con-
tent was measured by evaporative light scattering
detection (Varian 385-LC, Analytical Instruments
AS, Værløse, Denmark), using a reversed phase
C-5 column from Supelco© (Aldrich, Brøndby,
Denmark). Separation was achieved using a
0.8 ml/min flow rate with an isocratic mobile
phase of 75% methanol and 25% MilliQ water. The
injection volume was 50 μl, and external calibration
was performed with pure MDBGN.
Statistical data analysis. Results are expressed as
means ± standard error of the mean. Differences in
the patch test reactions were determined by two-
way analysis of variance (anova), with applied
dose and vehicle (ethosomes and ethanol/water) as
factors. ROAT experiments were analysed with the
Wilcoxon signed rank test. The graphpad prism 4
from GraphPad Software (San Diego, California,
USA) was used.
Results
Twenty subjects participated in the MDBGN patch
test and 18 in the ROAT study. One subject had
a negative patch test result and 8 subjects a nega-
tive ROAT result, and were excluded from further
analysis.
Eight subjects participated in the isoeugenol patch
test and ROAT, and all subjects had a positive patch
test reaction. Six subjects had a positive ROAT
reaction (one subject after 45 days), and two did
not react during the exposure period.
Isoeugenol and MDBGN formulated in etho-
somes gave significantly enhanced patch test
reactions as compared with the same allergens in
ethanol/water (Figs. 1 and 2). However, when POPC
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Fig. 1. Patch test results for methyldibromo glutaronitrile (MDBGN) (n = 19) and isoeugenol (n = 8) encapsulated in ethosomes
(100 mg/ml) as compared with the same concentrations of allergen in ethanol/water. Significant increases in patch test reactions
are seen for both allergens encapsulated in ethosomes (MDBGN, P < 0.0001; isoeugenol, P < 0.05). An increased allergen
concentration also increased the elicitation response (MDBGN, P < 0.0001; isoeugenol, P < 0.007) (two-way anova). Results are
expressed as means ± standard error of the mean.
Fig. 2. Result of a serial dilution patch test in a sensitized volunteer with methyldibromo glutaronitrile (MDBGN), using
IQ-chambers and 15 μl of test substance formulated in ethosomes and ethanol/water.
was added to ethanol/water – without extrusion of
vesicles – there was no difference in response to
isoeugenol in ethosomes (Fig. 3). The ROAT did
not show a significant difference for any of the
allergens, but a trend towards a more rapidly devel-
oping positive reaction was found for isoeugenol
formulated in ethosomes as compared with
isoeugenol formulated in ethanol/water (Table 1).
Characterization of ethosomes
Vesicle size measured before and after experiments
remained stable in the test tubes for the duration
of the experiment. All ethosomes were between
333 ± 13 and 463 ± 13 nm, and the PI ranged from
0.06 ± 0.04 to 0.22 ± 0.03. The PI values can be
regarded as monodisperse. The EE% of isoeugenol
in ethosomes was 77.3% ± 0.3%, and for MDBGN
it was 21.8% ± 4.3%.
Discussion
Using a protocol with precise dosing and char-
acterization of test preparations, we have, for the
first time, shown that lipophilic contact allergens
encapsulated in ethosomes can enhance patch test
reactions in sensitized individuals as compared
with the same allergens in a control solution of
40% ethanol in water without lipid vesicles. Other
vehicle effects on both sensitization and elicitation
responses have previously been reported in exper-
iments using the LLNA, guinea pigs and human
volunteers (14, 15). However, the effect of new
encapsulating vehicles has not been studied before.
No difference was seen when POPC was added
to the ethanol/water solution as compared with the
ethosome formulation (Fig. 3). A tentative expla-
nation of the results is that spontaneous formation
of vesicles occurs when POPC is mixed with
water (or ethanol/water). However, the vesicles
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Fig. 3. Patch test results with 6.5 mg/ml isoeugenol formulated in ethosomes (400 nm) and in 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC)/ethanol/water (n = 8). No significant difference was observed (Wilcoxon signed rank test). Results are
expressed as means ± standard error of the mean. The picture shows the light scattering effect of small extruded vesicles of 300 nm
(left) versus non-extruded vesicles (right).
Table 1. The repeated open application test (ROAT) performed
with isoeugenol (n = 6) and methyldibromo glutaronitrile
(MDBGN) (n = 10) formulated in ethosomes and ethanol/water
as vehicles
Days to positive ROAT ± SEM
Isoeugenol
Ethosomes 7.7 ± 2.4
Ethanol:water 15.3 ± 7.3
MDBGN
Ethosomes 10.7 ± 2.3
Ethanol:water 10.1 ± 2.0
Results are presented as mean days ± standard error of the mean
(SEM) to a positive reaction. No significant difference was observed
(Wilcoxon signed rank test) for either allergen, even though a
trend towards a faster developing reaction was seen for isoeugenol
formulated in ethosomes as compared with the ethanol/water
formulation (P = 0.31).
are not homogeneous in size, and they are mul-
tilamellar, whereas vesicles extruded through a
filter of equal pore size are more uniform and
unilamellar. The light scattering effect of small
extruded vesicles (300 nm) versus non-extruded
vesicles is clearly seen in Fig. 3. Owing to very
high PIs, DLS measurements were not applicable
for the POPC/ethanol:water formulation.
The ROAT performed with MDBGN and
isoeugenol with and without ethosomes showed
no significant difference in lag time until a positive
response, even though a trend towards a more
rapidly developing reaction occurred with encap-
sulated isoeugenol as compared with isoeugenol
in ethanol/water. We have no explanation for this
discrepancy between patch test results and the
ROAT, but occlusion may play a role. It has been
reported that occlusion decreases the penetration
of compounds through the skin when they are
encapsulated in Transfersomes© (16), but as there
is no clearly documented relationship between skin
penetration and the sensitizing capacity of an aller-
gen (17, 18), altered penetration is probably not
the key to the discrepancies in our results. Further
experiments are needed to clarify this issue.
Increased patch test reactivity correlates with
increased ROAT reactivity for some allergens, such
as MDBGN and isoeugenol (11, 19), but this is not
always the case (20). Isoeugenol is less lipophilic
and is better retained inside the ethosomes than
MDBGN, as expressed by higher EE% (77% ver-
sus 22%). Whether this difference accounts for
the discrepancy between the ROAT and patch test
reactions of MDBGN and isoeugenol encapsulated
in ethosomes remains speculative, but obviously the
low encapsulation efficiency of MDBGN is enough
to produce significant changes in the test reactions if
the encapsulation efficiency is an important param-
eter. A direct comparison is only valid for a single
allergen when formulated in different vehicles,
and not between different allergens, as allergens
with significantly different chemical structures, and
therefore physicochemical properties (e.g. log P),
will influence the vesicle properties (e.g. stabil-
ity, encapsulation efficiency, and skin penetration)
and subsequently complicate discussions on the
findings.
The clinical implications of these results are,
so far, uncertain. However, the cosmetic industry
should consider the effect of encapsulation on a
case by case basis, because certain ingredients
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may become more allergenic when encapsulated.
Dermatologists using encapsulation technology
to investigate patients with allergic reactions to
consumer products should consider the risk of
false-negative results, if testing with ingredients
in conventional patch test vehicles. Testing with
encapsulated ingredients should be performed when
possible.
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Introduction
In order for a contact allergen to get in contact with 
the cutaneous immune system, it has to penetrate 
the viable epidermis. Thus, allergens should have 
appropriate physicochemical properties to cross the 
stratum  corneum, which normally is an effective 
skin barrier. A certain degree of lipophilicity (logP 
[logarithm of the ratio of the concentrations of the un-
ionized solute in solvents] around 2) is advantageous. 
Cutaneous and Ocular Toxicology, 2010, 1–7, Early Online
R E S E A R C H  A R T I C L E
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Abstract
Background: Formulation of the contact allergens dinitrochlorobenzene and isoeugenol in ethanolic lipo-
somes (ethosomes) increases their sensitizing properties in the local lymph node assay compared with an 
ethanol–water formulation of the allergens. Likewise, isoeugenol and methyldibromo-glutaronitrile for-
mulated in ethosomes enhanced the patch test reactions in sensitized human volunteers. The relationship 
between the percutaneous penetration/absorption and sensitization/elicitation phases of contact allergy 
is not well elucidated.
Objective: The aim of this study was to investigate whether the observed increased sensitizing and elicitation 
properties following the formulation of selected contact allergens in ethosomes could be explained by a 
change in release kinetics of the allergens and their pattern of percutaneous penetration and absorption 
as well as allergen deposition in epidermis and dermis.
Methods: Release kinetics were studied using dialysis bags, and samples were taken at selected time points 
until equilibrium was reached. Percutaneous absorption and penetration were studied using human skin 
on Franz cells, and receptor fluid samples were taken at selected time points. Experiments were terminated 
after 24 hours, and deposition of allergen in epidermis and dermis was measured. Maximum flux and lag 
time were calculated.
Results: Ethosome formulation decreased the release of both allergens compared with the ethanol–water 
formulation. Ethosome formulation of dinitrochlorobenzene increased its percutaneous penetration but 
reduced the percutaneous penetration of isoeugenol compared with control formulations. Likewise, all other 
calculated parameters showed an opposite trend for the 2 allergens in ethosomes and ethanol–water.
Conclusions: The present study demonstrates that identical ethosomes affect the percutaneous penetration 
characteristics of 2 allergens differently. Thus, our results indicate that each combination of an allergen 
and a vehicle needs to be evaluated separately. The exact mechanistic relationship between percutaneous 
penetration, release kinetics, and allergenicity of chemicals in various vehicles remains to be clarified.
Keywords: Percutaneous absorption; ethosomes; liposomes; allergen; sensitization; Franz cell
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Extremely lipophilic and hydrophilic molecules are 
poor skin penetrators (1,2). Formulating a chemi-
cal/ allergen in different vehicles for topical adminis-
tration may change the skin penetration profile (2–4) 
and the sensitizing and elicitation capacity of the 
allergen (5–9), but how these outcomes are related 
to penetration and absorption properties is not well 
elucidated.
We have previously shown that formulation of 
contact allergens (dinitrochlorobenzene [DNCB] 
and isoeugenol) in ethanolic liposomes (ethoso-
mes) increased the sensitizing properties in the local 
lymph node assay (LLNA) and that isoeugenol and 
methyldibromo-glutaronitrile formulated in etho-
somes enhanced the patch test reactions in 27 sen-
sitized human volunteers (2,10,11). Several reports 
have shown that encapsulating lipophilic and cati-
onic compounds in ethosomes increases their skin 
penetration and bioavailability in stratum corneum 
compared with formulations without ethosomes (12). 
The aim of this study was to investigate whether the 
observation of increased sensitizing and elicitation 
properties following formulation of selected con-
tact allergens in ethosomes could be explained by a 
change in release kinetics and penetration pattern. 
We used dialysis and Franz diffusion cells and com-
pared release kinetics and penetration profiles of 2 
ethosome-encapsulated contact allergens with the 
same contact allergens formulated in ethanol–water 
making the lipids (ethosomes) the only difference.
Methods
Ethosome preparation
Ethosomes with isoeugenol (Sigma-Aldrich Denmark 
A/S, Copenhagen, Denmark; Chemical Abstract 
Service [CAS] No. 97-54-1) or DNCB (Sigma-Aldrich 
Denmark A/S; CAS No. 97-00-7) were prepared as 
described by Touitou et al. (13). Briefly, 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC; Avanti 
Polar Lipids, (Alabaster, AL, USA) was dissolved in 96% 
ethanol containing isoeugenol or DNCB, and Milli-Q 
water (Millipore Corp., Billerica, MA, USA) was added 
slowly to a final concentration of 40% (percent volume 
in volume [v/v]) ethanol. The suspension extruded 10 
times through 2 polycarbonate filters with a pore size 
of 200 nm using a Lipex Extruder (Northern Lipids 
Inc. Burnaby, BC, Canada). The concentration of 
isoeugenol and DNCB in experimental solutions was 
determined by high-performance liquid chromatogra-
phy (HPLC). The DNCB or isoeugenol was dissolved 
in ethanol after Milli-Q water was added to a final 
concentration of 40% (v/v) ethanol. The ethosome 
preparation was compared with a 4:6 ethanol-to-water 
solution containing isoeugenol or DNCB.
Characterization of ethosomes
The hydrodynamic particle diameters and polydis-
persity index (PI) of ethosomes, which describes the 
size distribution of the particles, were determined 
by dynamic light scattering (DLS) using a BI-200SM 
instrument from Brookhaven Instruments (Holtsville, 
NY, USA). This incorporates a 632.8-nm helium–neon 
(HeNe) laser operating at a fixed scattering angle of 
90°. Twenty-microliter ethosome solution was diluted 
in 1.5 mL of ethanol–Milli-Q water (4,6). The measure-
ments were conducted in triplicate in a multimodal 
mode of 180 seconds. The sizes of the ethosomes were 
measured on the day of preparation and immediately 
after the experiments.
Encapsulation efficiency
The encapsulation efficiency (EE%) of isoeugenol 
and DNCB by ethosomal vesicles was determined by 
ultracentrifugation as described by Heeremans et al. 
(14) and later used on ethosomal systems by Touitou 
et al. (13). Ethosomal preparations containing DNCB 
or isoeugenol were kept for 12 hours at 5°C and there-
after spun at 40,000 revolutions per minute (RPM) 
for 3 hours in a Hitachi Sorvall Discovery 90SE ultra-
centrifuge (Tokyo, Japan) with a swing-out rotor from 
Sorvall (SW50.1; Thermo Fisher Scientific, Asheville, 
NC, USA). The supernatant was immediately removed 
and the allergen quantity was determined in both the 
sediment and the supernatant. Binding efficiency was 
calculated as follows:
[(T C) T] 100− / ×
 where T is the total amount of chemical detected 
in both the supernatant and sediment, and C is the 
amount of chemical detected only in the supernatant. 
The procedure was done in triplicate.
Quantification of isoeugenol and 
dinitrochlorobenzene in ethosomes
High-performance liquid chromatography analysis 
was conducted on an ultimate 3000 series from Dionex 
Corporation (Sunnyvale, CA, USA) with a diode array 
detector. A Dionex RP-18 Acclaim 300 C18  reversed-phase 
column was used. The temperature of the column and 
the sample rack in the autosampler was set to 20°C. The 
autosampler mobile phase included 75% methanol and 
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25% Milli-Q water; isocratic  elution for 30 minutes; and a 
flow rate of 1 mL/min. The separations were monitored 
at 270 nm. The injection volume was 10 µL. Pure refer-
ence compounds were used to make external calibra-
tion curves from which the  concentrations of DNCB and 
isoeugenol were determined.
Skin membranes
The human skin samples were obtained from the 
Department of Plastic and Reconstructive Surgery, 
Odense University Hospital. Skin was sampled from 
3 women (26–37 years old) who underwent breast 
reconstruction. Skin samples were kept at −20°C 
for periods not exceeding 12 months. The skin was 
allowed to thaw at room temperature 1 hour before 
being cleaned with distilled water. Subcutaneous fat 
was removed. Skin thickness varied between 0.90 and 
0.96 mm. Skin samples from individual donors were 
equally distributed between experimental groups.
Skin penetration and absorption model
Percutaneous penetration experiments were carried 
out using Franz diffusion cells with a permeation area 
of 2.12 cm2 and a receptor volume between 15 and 
19 mL (measured for each individual cell) as described 
by Nielsen et al. (2). The system consists of 2 half-cells 
where the upper cell compartment represents the 
donor chamber and the lower, the receptor chamber. 
The cells were kept at a constant temperature (32°C) in 
a water bath with individual magnetic stirring. Prior to 
experiments, the epidermal site was exposed to ambi-
ent laboratory conditions and the dermis was exposed 
to an aqueous solution of 0.9% sodium chloride (NaCl) 
and 5% bovine serum albumin (BSA)-containing 10% 
ethanol for 18 hours. Further, the barrier integrity 
was evaluated by capacitance measurements (Lutron 
DM-9023, Acer AB, Bromma, Sweden) before the expo-
sure to test substances, and cells with a capacitance 
above 110 nF were excluded.
During the experimental periods, donor and recep-
tor chambers were covered with parafilm to avoid 
evaporation. The skin was exposed to 106 µL of test 
substance (50 µL/cm2) and samples of 1 mL where 
taken at 2, 4, 6, 12, and 24 hours from the receptor 
chamber and replaced with 1 mL of fresh receptor 
fluid. At the end of the experiment, remaining test 
compound in the donor chamber and on top of the 
skin was sampled using repeated washings with cot-
ton swabs and 50% acetonitrile. Cotton swabs and skin 
samples were left for 72 hours to extract in acetonitrile 
before chemical analysis.
After termination of the experiments, the epidermis 
was gently removed from the skin samples with a sharp 
knife, and both dermis and epidermis were transferred 
to individual vials containing 100% acetonitrile and 
left for extraction for 27 hours before measuring the 
amount of DNCB or isoeugenol.
The adherence of test compounds to glass in the 
receptor chamber, to proteins in the receptor fluid, 
and to the skin after extraction procedures was evalu-
ated to ensure complete recovery of penetrated test 
compounds.
The amount of DNCB applied in ethanol–water was 
0.035 mg and 0.036 mg in ethosomes. The amount of 
isoeugenol applied in ethanol–water was 1.58 mg and 
1.24 mg when applied in ethosomes.
Release kinetics
Dialysis membranes (Spectra-por 6, pore size: 10,000 
daltons, Spectrum Labs, purchased from Bie & 
Berntsen AS, Herlev, Denmark) were filled with 300 µL 
of test solution of DNCB or isoeugenol formulated in 
ethanol–water, 30, 60 or 90 mg/mL ethosomes, and left 
in 75 mL of ethanol–water (4:6 v/v) on a magnetic stir-
rer. Samples of 500 µL were taken out at specific time 
intervals (Figure 2) and replaced with an equal amount 
of ethanol–water. Samples were analyzed by HPLC and 
expressed as the percentage of the applied amount of 
allergen. The concentration of DNCB was 0.79 mg/ mL 
in ethanol–water, 0.67 mg/mL in 30-mg/ mL etho-
somes, 0.62 mg/mL in 60-mg/mL ethosomes, and 
0.63 mg/mL in 90-mg/mL ethosomes. The concentra-
tion of isoeugenol was 8.79 mg/mL in ethanol–water, 
8.79 mg/mL in 30-mg/mL ethosomes, 7.23 mg/mL in 
60-mg/mL ethosomes, and 7.63 mg/mL in 90-mg/mL 
ethosomes.
A T50% value was calculated in a way similar to the 
EC3 value (concentration of test chemical required to 
provoke a 3-fold increase in lymph node cell prolifera-
tion) of the LLNA (15), with the T50% value being an 
estimate of the time needed for 50% of the allergen to 
diffuse through the dialysis membrane.
Statistical data analysis
Results are expressed as mean ± standard error of the 
mean (SEM) or standard deviation (SD). Statistically 
significant differences in penetration over time 
of isoeugenol and DNCB and the release kinetics 
were determined using 2-way analysis of variance 
(ANOVA). The Mann-Whitney test was used to test 
for different amounts of allergen stored in epidermal 
and dermal compartments for ethanol–water and 
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ethosomal formulations. A p-value < .05 was chosen 
as the minimal level of significance. Differences of the 
T50% values were determined by 1-way ANOVA. We 
used the statistical software package GraphPad Prism 
4 from GraphPad Software Inc. (La Jolla, CA, USA).
Results
Ethosome formulation of DNCB significantly increased 
the percutaneous absorption of DNCB compared with 
an ethanol–water formulation of DNCB (Figure 1, 
Table 1). In contrast, the percutaneous absorption of 
isoeugenol formulated in ethosomes was significantly 
reduced compared with an ethanol–water formula-
tion of isoeugenol (Figure 1, Table 1). The DNCB for-
mulated in ethosomes had a slight (nonsignificant) 
increase in dermis deposition compared with the 
ethanol–water formulation, but no difference in epi-
dermal deposition (Table 1). On the contrary, the etho-
some formulation significantly decreased the dermis 
deposition of isoeugenol and caused a more limited 
and nonsignificant increase in epidermal deposition 
of isoeugenol. The ethosome formulation caused a 
significant increase in the relative skin deposition of 
isoeugenol, whereas the ethosomes had a more limited 
but opposite effect on the relative skin deposition of 
DNCB (Table 1). A significantly increased lag time was 
found for isoeugenol formulated in ethosomes com-
pared with the ethanol–water formulation, whereas 
the lag time of DNCB was not significantly affected by 
the ethosome formulation. The maximum flux as well 
as the permeability coefficient of isoeugenol was sig-
nificantly lower, when isoeugenol was formulated with 
ethosomes compared with the ethanol–water formu-
lation, whereas no difference was seen for the DNCB 
formulations. In summary, all parameters showed an 
opposite trend for the 2 allergens in ethosomes and 
ethanol–water. No measurable adherence of DNCB or 
isoeugenol to glass, protein binding, or remaining test 
compounds in skin samples following the extraction 
procedures were observed.
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Figure 1. The graph on the left shows a significantly increased percutaneous absorption after 12 hours when dinitrochlorobenzene (DNCB) 
is formulated in ethosomes compared with an ethanol–water formulation, and the graph on the right shows a significantly decreased 
percutaneous absorption after 8 hours when isoeugenol is formulated in ethosomes compared with an ethanol–water formulation (n = 8, 
**p < .01, ***p < .001, 2-way analysis of variance). Results are expressed as mean ± standard error of the mean.
Table 1. Fraction of dinitrochlorobenzene and isoeugenol retained in epidermis and dermis after 24 hours treatment of dinitrochlorobenzene 
and isoeugenol formulated in ethosomes and ethanol–water.
  
Epidermis 
deposition  
(µg/cm2)
Dermis  
deposition  
(µg/cm2)
Dermis/ 
epidermis 
ratio
Total  
percutaneous 
absorption at  
24 h/(µg/cm2)
Total skin 
deposition in 
percent of total 
penetration
Maximum 
flux  
(µg/cm2·h)
Lag time  
(h)
K
p
  
(µm/h)
DNCB Ethanol–water 0.05 ± 0.04 0.66 ± 0.32 17.9 ± 10.7 34 ± 4 2.09 ± 0.96 1.3 ± 0.6 2.4 ± 0.9 39 ± 17
Ethosomes 0.04 ± 0.01 0.82 ± 0.42 19.7 ± 7.8 59 ± 16*** 1.68 ± 1.31 1.6 ± 0.8 1.9 ± 1.2 47 ± 24
Isoeugenol Ethanol–water 2.83 ± 1.57 49 ± 21 18.7 ± 6.6 4,635 ± 1,167 1.30 ± 1.00 206 ± 91 4.5 ± 1.1 138 ± 61
Ethosomes 3.30 ± 1.58 22 ± 6** 8.7 ± 5.9** 1,327 ± 443*** 2.05 ± 0.55* 69 ± 21* 6.8 ± 1.4** 59 ± 18*
Data are expressed as µg ± standard deviation (n = 8).
*p < .05.
**p < .01.
***p < .001.
DNCB = dinitrochlorobenzene; K
p
 = permeability coefficient.
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The dialysis experiment showed increasing T50% 
values with increasing amounts of ethosomes in the 
sample (Table 2). This observation is a consequence 
of the decreased release rate when DNCB as well as 
isoeugenol was formulated in ethosomes (Figure 2). 
An interesting observation was that the effect of etho-
some formulation was evident at the lowest concentra-
tion of ethosomes applied for isoeugenol (30 mg/mL), 
whereas a 3-times higher concentration of ethosomes 
was required to decrease the release rate significantly 
for DNCB (Table 2).
Size and encapsulation efficiencies show that etho-
somes loaded with isoeugenol are slightly larger than 
DNCB-loaded ethosomes (Table 3). Encapsulation 
efficiencies are of the same magnitude.
Discussion
We found contradictory percutaneous absorption 
and penetration patterns when comparing DNCB 
and isoeugenol formulated in ethanol–water and 
 ethosomes and hence penetration/absorption char-
acteristics could not explain the increased sensitiz-
ing capacity of both allergens when formulated in 
ethosomes. A marked difference between DNCB and 
isoeugenol is in the water solubility, with isoeugenol 
being much more water-soluble than DNCB. Further, 
isoeugenol has higher logP and lower encapsulation 
efficiency than DNCB, but both allergens showed 
a sustained release when formulated in ethosomes 
(Table 3). Despite these differences, both allergens 
increase their sensitizing potential when formulated 
in ethosomes, suggesting that the sustained release 
might be an important parameter of the observed dif-
ferences in sensitizing capacity. All previously pub-
lished studies investigating ethosome formulations 
and skin penetration show an increased penetration/
absorption of the encapsulated compound. We have 
shown for the first time that an ethosome formulation 
of a compound (isoeugenol) inhibited the percutane-
ous penetration compared with a control formulation 
without the vesicles. Andersen et al. showed in 1985 
that chlorocresol formulated in propylene glycol had 
a lower sensitization capacity compared with an ace-
tone–olive oil formulation. Both formulations had the 
same bioavailability of chlorocresol in the skin after 
24 hours, but the authors did not distinguish between 
skin deposition and did not measure skin absorption 
(16). In 1996, Heylings et al. investigated the vehicle 
effects of DNCB formulated in acetone and propylene 
glycol and skin absorption in the LLNA (17). They 
found an increased sensitizing capacity, which corre-
lated with an increased flux from 2 hours and onwards 
when DNCB was formulated in acetone compared 
with propylene glycol, the latter having the lowest 
EC3 value. After 24 hours, the total skin absorptions 
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Figure 2. The release time for dinitrochlorobenzene (DNCB) and isoeugenol in an ethanol–water formulation and in 3 concentrations 
of ethosomes evaluated by dialysis. Both allergens are released significantly slower when formulated in increasing concentrations of 
ethosomes. Data represents mean ± standard error of the mean (n = 3, p < .0001 for DNCB and p < .0025 for isoeugenol, 2-way analysis of 
variance). POPC = 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.
Table 2. Dialysis experiments show increasing T50% values with 
increasing amount of ethosomes in the sample.
T50%
POPC (mg/mL)
0 30 60 90
DNCB 10 ± 1 14 ± 1 21 ± 15 33 ± 9
Isoeugenol 10 ± 1 32 ± 6* 26 ± 5** 44 ± 8***
Data represent mean ± standard deviation; N = 3; one-way analysis 
of variance with Newman-Keuls post hoc test.
*p < .05.
**p < .01.
***p < .001.
DNCB = dinitrochlorobenzene; POPC = 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine; T50% = estimation of the time 
needed for 50% of the allergen to diffuse through the dialysis 
membrane.
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were similar for the 2 formulations (17). Further, the 
percentage of the applied dose absorbed through the 
skin at 4 hours was substantially greater when DNCB 
was administered in acetone (17). For both vehicles, 
similar amounts of DNCB were found on top of the 
skin at 4 hours, but markedly less had penetrated into 
or beyond the skin when propylene glycol was used 
as the vehicle, suggesting that increased absorption at 
4 hours may be more important than the absorption 
profile after 24 hours. We found comparable fluxes 
from 2 to 8 hours for DNCB formulated in ethosomes 
and ethanol–water. Beyond 8 hours, only a slight 
increase in flux was seen for the ethosome formula-
tion. On the contrary, we found a significant decrease 
in flux and lag time when isoeugenol was formulated 
in ethosomes compared with ethanol–water, resulting 
in a lower permeability coefficient (k
p
).
Pendlington et al. studied the sensitizer hexyl cin-
namic aldehyde (HCA) in 4 different vehicles (18), of 
which 3 previously had been tested using the LLNA 
(7) in an attempt to study the epidermal/dermal dis-
position of the allergen. The authors did not, however, 
correlate the skin deposition of HCA in the 3 vehicles 
to the EC3 values of HCA in the different vehicles. 
When correlating the sensitizing potency of HCA in 
the 3 vehicles (in order of increasing potency: acetone–
olive oil, propylene glycol, and ethanol) and skin dis-
position of HCA, a consistent correlation was found 
between low EC3 value and high flux (0–6 hours) and 
high cumulative skin absorption, but not between low 
EC3 value and HCA deposition in stratum corneum, 
epidermis, and dermis. This is largely consistent with 
Heylings et al.’s finding that the flux is important, but 
not with our findings.
In conclusion, there is no simple relationship 
between bioavailability, skin absorption, and sensitiz-
ing capacity of contact allergens in different formula-
tions. It appears that the first hours of skin penetration 
are decisive for sensitization development. In this study 
we focused on 24 hours’ data for the skin deposition. It 
would be interesting to study allergen skin deposition 
from 0 to 8 hours. Ethosome formulations may affect 
allergen concentration deeper in the epidermis or der-
mis within this spectrum of time. New visualization 
techniques such as confocal and 2-photon microscopy 
allow real-time noninvasive measurements of the pen-
etration of fluorescent allergens in the different skin 
departments over time (19) and would be a suitable 
method for such studies. The time points of interest 
regarding penetration behavior of allergens may be the 
first hours after topical application.
It has been stated that skin penetration/absorp-
tion of allergens is of only minor importance, for 
an extremely strong sensitizer such as trimellitic 
anhydride, with a logP value of −2.5, because it 
would be considered too hydrophilic to penetrate 
readily (20). Vehicle effects have been studied exten-
sively using the mouse LLNA. No cases have been 
reported where a compound classified as a weak 
sensitizer in one vehicle was classified as a strong 
sensitizer in another vehicle (6,7,21). It has been 
suggested that the enhanced lymph node cell pro-
liferative responses induced by DNCB when applied 
in sodium lauryl sulfate may be due to increased 
numbers of dendritic cells reaching the lymph nodes 
(22). Further, it has been postulated that the vehicle 
in which DNCB is delivered to the skin may influence 
cutaneous metabolism secondary to, or independ-
ent of, altered absorption kinetics (17). Presumably 
similar mechanisms could explain the consistently 
higher sensitizing capacity found in the LLNA when 
a lipophilic allergen is formulated in ethosomes com-
pared with ethanol–water solution. The mechanisms 
of allergic contact allergy are complex, and perhaps 
it is the unique combination of allergen and vehicle 
that determines the sensitizing and elicitation prop-
erties and not just the skin penetration/absorption 
 characteristics of the allergen alone.
Table 3. Overview of physical–chemical properties, size of ethosomes, skin penetration formulated in ethosomes, and release time 
formulated in ethosomes of isoeugenol and dinitrochlorobenzene.
 DNCB Isoeugenol
Molecular weight 202.5 164.21
Water solubility Insoluble Slightly soluble
LogP (O:W) 2.17a 3.04a
Encapsulation efficiency in ethosomes (%) 90 ± 0.3b 77 ± 0.3b
Release time when formulated in ethosomes compared with ethanol–water Increased Increased
Skin penetration when formulated in ethosomes compared with ethanol–water Increased Decreased
Size of ethosomes (nm) 245 ± 17b 396 ± 20b
aIndicates experimental values obtained using the following software: US EPA. Estimation Programs Interface Suite for Microsoft Windows, 
version 4.00. Washington, DC: United States Environmental Protection Agency, 2010.
bData represent mean ± standard deviation (N = 3).
DNCB = dinitrochlorobenzene; LogP = logarithm of the ratio of the concentrations of the un-ionized solute in solvents.
O:W = Octanol-Water Partition Coefficient
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Formulating DNCB and isoeugenol in ethosomes 
increased the release time of the allergens from the 
dialysis bag (Figure 2). It took more than 1 hour before 
the released amount of allergen from the ethosome 
formulation reached the amount of ethanol–water for-
mulation. The speed of release of allergen from the for-
mulation is perhaps more important than the speed of 
penetration when comparing sensitization properties 
in different vehicles. However, the exact mechanism 
of how a vehicle influences the sensitizing properties 
remains uncertain. The present study on 2 different 
allergens suggests that skin penetration properties on 
a wider scale (not just amount, but also kinetics) are 
important parameters in relation to understanding the 
allergenicity of chemicals in  various vehicles.
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REVIEW
Microvesicle Formulations Used in Topical Drugs and
Cosmetics Affect Product Efficiency, Performance and
Allergenicity
Jakob Torp Madsen and Klaus Ejner Andersen
Attempts to improve the formulations of topical products are continuing processes (ie, to increase cosmetic performance, enhance
effects, and protect ingredients from degradation). The development of micro- and nanovesicular systems has led to the marketing of
topical drugs and cosmetics that use these technologies. Several articles have reported improved clinical efficacy by the
encapsulation of pharmaceuticals in vesicular systems, and the numbers of publications and patents are rising. Some vesicular
systems may deliver the drug deeper in the skin as compared to conventional vehicles, or even make transdermal delivery more
efficient for a number of drugs. Vesicular systems may also allow a more precise drug delivery to the site of action (ie, the hair
follicles) and thereby minimize the applied drug concentration, reducing potential side effects. On the other hand, this may increase
the risk of other side effects. Few case reports have suggested that microvesicle formulations may affect the allergenicity of topical
products. This article gives an overview of the current knowledge about the topical use of microvesicular systems and the
dermatoallergologic aspects.
T HE DEVELOPMENT of new formulations for topicalproducts is a continuing process. The encapsulation of
product ingredients into different carrier molecules (such as
liposomes) may improve product efficiency and is a
promising tool for dermal and transdermal delivery of
drugs and cosmetic ingredients. The encapsulation technol-
ogy has been used since the late 1960s, and several topical
products marketed today claim benefits from this technol-
ogy. This review focuses on the use of different types of
encapsulating technologies in topical drugs and cosmetics
and describes their possible effects on product allergenicity.
Encapsulation Technology Used in Topical Drugs
and Cosmetics
One advantage of encapsulating a drug into liposomes is
the possibility of delivering the drug directly to the site of
action in the skin at a higher concentration and obtaining
a decreased percutaneous absorption at the same time. The
penetration pattern is determined by the composition of the
liposome and the encapsulated compound. It is difficult to
get approval from health service authorities for topical
drugs using encapsulation technology because it is prob-
lematic for the manufacturer to prove the presence and
stability of the microvesicles in the product. Some
pharmaceutical products using microvesicle carriers are
commercially available; examples are Pevaryl Lipogel (Cilag
Corp., Schaffhausen, Switzerland), which is econazole
encapsulated in liposomes, and a local anesthetic formu-
lated in liposomes (LMX4, Ferndale Pharmaceuticals Ltd,
UK). Estrasorb (Graceway Pharmaceuticals, Exton, PA) is
estradiol encapsulated in micelles in a nanoemulsion for
transdermal drug delivery; it is used for reducing hot flares
in menopausal women.1
Several clinical trials have shown improved biologic
effects of products with microvesicle formulations as
compared to products with conventional formulations
(for treatment of herpes simplex, psoriasis, acne, xerosis,
atopic dermatitis, vitiligo, and superficial thrombophlebi-
tis2–5). An example is 5-aminolevulinic acid formulated in
50 nm liposomes, which gives a more precise drug delivery
that allows a 40% reduction in the amount of active
ingredient when used to treat acne with photodynamic
therapy. The liposomes concentrate in the pilosebaceous
units, thereby reducing side effects and opening doors for
new treatment modalities.6 Another example is the topical
administration of methotrexate (MTX), which is hydro-
philic and present in dissociated form at physiologic
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hydrogen ion concentration (pH); its capacity for passive
diffusion is thus limited. Clinical trials have shown better
efficacy of MTX encapsulated in liposomes when com-
pared to placebo and marketed MTX gel, probably owing
to increased bioavailability.2
The carrier particles themselves are all considered safe
for topical use, but the interaction between the carrier
particle and the active ingredient may cause biologic effects
due to altered skin penetration, release profile, and
deposition of the active ingredients.
Lipid vesicles, solid lipid nanoparticles, and polymeric
nanoparticles are used in cosmetic formulations to
increase bioavailability in stratum corneum and to protect
light- and oxygen-sensitive cosmetic ingredients against
degradation.7 Cosmetic ingredients such as retinyl palmi-
tate may cause physiologic changes of the skin but are not
claimed to treat skin diseases. Examples of encapsulated
cosmetic ingredients are numerous (eg, coenzyme Q10,
ascorbyl palmitate, tocopherol [vitamin E], and retinol
[vitamin A]).8,9 The types of nanoparticles and micro-
particles discussed below are components of marketed
cosmetics.
Liposomes
Liposomes are produced in sizes ranging from 25 nm to
several micrometers. They consist of a single or multiple
lipid double layer (unilamellar or multilamellar vesicles).
Liposomes are capable of carrying amphiphilic active
ingredients either in the lipid layer or in the hydrophilic
core. They are believed to protect the active ingredients
from degradation. Liposomes tend to break down into
their constituent components when in contact with the
skin. Therefore, liposomes at best can modulate drug
transport to stratum corneum, but penetration will
require more-stable carriers such as solid lipid nanopar-
ticles or Transfersomes.10 The concentration of active
ingredients in the epidermis may be up to five times
greater with liposome formulations than with formula-
tions that use more-conventional vehicles.11 Liposome
formulation in water can easily be incorporated in an
aqueous cream for better cosmetic performance. In the
cosmetic industry, examples of active ingredients incor-
porated in liposomes are antioxidants, vitamin A deriva-
tives, and vitamin E.
Transfersomes
Vesicles produced by adding different amounts of so-called
edge activators to the bilayer of classic liposomes (eg,
cholesterol or sodium cholate and a small concentration of
ethanol) are called Transfersomes and Flexosomes. The
edge activators destabilize the membrane, creating a more
flexible structure, and have been shown to penetrate in
stratum corneum better as compared to classic liposomes,
thereby delivering their encapsulated ingredients deeper in
the epidermis but not to the blood circulation.12 The
mechanism of enhancement of skin penetration has not
been completely elucidated, but because of their flexibility,
Transfersomes are believed to squeeze between the cor-
neocytes, driven by an osmotic force due to the difference
in water content of the relatively dehydrated epidermis and
the viable dermis.13 Because of that theory, Transfersomes
should not be applied under occluded conditions, which
abolishes the osmotic effect. Several drugs encapsulated
in Transfersomes (eg, nonsteroidal antiinflammatory
drugs [NSAIDs] and local anesthetics) have been tested
in animal experiments and showed increased dermal
delivery and clinical effect when compared to conventional
formulations.12
Ethosomes
Ethosomes are nanocarriers made of phospholipids,
ethanol at a high concentration (20–50%), and water.
They can deliver drugs to the deep skin layers and the
systemic circulation. Ethosomes have a much higher
loading capacity of lipophilic drugs as compared to classic
liposomes. A clinical trial showed that treatment with
ethosomal encapsulated acyclovir significantly improved a
herpetic infection when compared to treatment with the
traditional Zovirax (GlaxoSmithKline, Brentford, UK)
cream with the same concentration of active drug.
Insulin-loaded ethosomes have been found to be suitable
for systemic transdermal delivery, and the antibiotic
bacitracin has likewise been encapsulated in ethosomes
and reaches the deep layers of the skin in animal
experiments. Ethosomes may play a role in future
transdermal drug delivery.14 Examples of cosmetics using
ethosomes are Lipoduction (Osmotics, New York, NY)
and Noicellex (Novel Therapeutic Technologies, Inc.,
Wilmington, DE).
Niosomes
Niosomes consist of non-ionic surfactant vesicles and are
an alternative to liposomes. They can entrap both
hydrophilic and hydrophobic chemicals, enhance delivery
to the skin, and sustain the release of the drug. A phase I
and II study in psoriasis patients concluded that MTX-
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loaded niosomes are more efficacious than marketed MTX
gel.2
Solid Lipid Nanoparticles
Solid lipid nanoparticles (SLNs) were developed in the
1990s and are produced by replacing the liquid lipid in an
oil-in-water emulsion with a lipid that is solid at both
room and body temperature. The incorporation of
pharmaceuticals and cosmetics in SLNs is feasible and
can easily be formulated in a cream.15 An advantage of
SLNs compared to conventional creams is an increase in
skin hydration owing to a better occlusive effect by SLNs.16
Burst or sustained release of incorporated ingredients has
been reported, as well as increased percutaneous absorp-
tion as compared to conventional formulations; this is
probably due to the unique composition of the SLN and
incorporated ingredient. Examples of pharmaceuticals
formulated in SLNs are podophyllotoxin, antimycotics,
NSAIDs, psoralen, and topical glucocorticoids. No human
studies with pharmaceuticals incorporated in SLNs have
been performed yet, but more than 30 cosmetic products
containing SLNs were marketed in 2008.17 No side effects
have been reported.
Nanoemulsions
Nanoemulsions consist of two phases, with droplets of 50
to 100 nm in the external phase. Emulsifiers that are used
to bind together oil and water in products such as hair
conditioners and makeup removers yield a less oily
mixture when they are broken down into nanoparticles.
Nanoemulsions are used in both rinse-off and stay-on
products. Opposing results are obtained on the relation
between emulsion droplet size and the depth of dermal
penetration of the active ingredients. Nanoemulsions
increase the transdermal bioavailability of vitamin E,18
but penetration of tetracaine from nanoemulsion is not
affected by a droplet size of 100 to 3,500 nm on the skin.19
Different emulsion components have been used, and other
authors have found increasing transdermal penetration
with decreasing droplet size. There is so far no simple
relationship between chemical, particle size, and penetra-
tion, and each new emulsion carrying different active
ingredients must be investigated separately to ascertain its
skin penetration pattern.
Nanospheres
Nanospheres are produced from different polymers (eg,
polycaprolactone, a biodegradable product widely used in
the cosmetic industry). When produced, the polymer
wraps around itself, creating lipo- and hydrophilic spaces.
Several drugs have been incorporated in nanospheres,20 as
have cosmetic ingredients.21 L’O´real (Paris, France) has
developed a nanocarrier system called Nanosome, which
consists of the biodegradable polymer polycaprolactone;
other cosmetic companies have developed similar pro-
ducts. Polycaprolactone nanoparticles loaded with the
lipophilic dyeing agent nile red showed enhanced penetra-
tion of the molecule into the stratum corneum layers (up
to 60 mm) as compared to non-nanoparticle formula-
tions.22,23 The distribution of another topically applied
nanosphere nile red formulation was studied in human
cadaver skin with cryosectioning and fluorescence micro-
scopy by Sheihet and colleagues.24 Permeation analysis
revealed that the nanospheres delivered nine times more
nile red to the lower dermis than a control formulation
using propylene glycol did. Few articles have been
published about penetration and absorption in skin and
the clinical effect of carrier molecules manufactured by
cosmetic companies.
Dermatitis Related to Exposure to Products
Containing Microvesicles
Few case reports have suggested that microvesicles in
topical products may have been involved in the develop-
ment of allergic contact dermatitis. Propyl gallate incor-
porated in liposomes has been suggested to boost the
allergic potential of propyl gallate in 13 patients; however,
patch tests with and without the liposomal formulation
were not performed.25 Another case report described a
woman who developed severe allergic contact dermatitis
from an antiwrinkle cream containing retinyl palmitate
encapsulated in polycaprolactone.21 Polycaprolactone is a
polymeric drug delivery system capable of encapsulating
lipo- and hydrophilic agents. Retinyl palmitate is a rare
contact allergen, and diagnostic patch tests revealed that
the patient reacted more strongly to encapsulated retinyl
palmitate than to retinyl palmitate in petrolatum, even
though the retinyl palmitate concentration was much
lower when formulated in polycaprolactone when com-
pared to the petrolatum formulation (Fig 1).
Enhanced Allergenicity of Compounds Encapsulated
in Microvesicle Formulations
Increased sensitization response was found by local lymph
node assay (LLNA) when dinitrochlorobenzene and
isoeugenol encapsulated in ethosomes were compared to
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formulations without ethosomes.26 Controlled patch-test
experiments in selected sensitized volunteer patients and
using ethosomes loaded with methyldibromoglutaronitrile
or isoeugenol showed enhanced patch-test responses in
comparison to patch tests with the same allergens in
ethanol and water (4:6) formulations, making the vesicles
the only difference.27 Vehicle effects on both sensitization
and elicitation responses in experiments using LLNA and
human volunteers as test subjects were previously
reported.28,29 However, the effect of new encapsulating
vehicles on product allergenicity is rarely studied. The
particles in these experiments exceeded the 100 nm size
limit for nanoparticles. However, particles larger than 100
nm also may show size-specific properties; for example,
liposomes of 120 nm penetrate human skin to a greater
extent than do liposomes of 810 nm.30 So far, no reports
have suggested that vesicles of nanosize range increase the
skin penetration of encapsulated compounds as compared
to similar formulations without the nano-sized vesicles.
Conclusion
The dermatotoxicologic risk from skin exposure to micro-
vesicle carrier systems is considered to be low. No general
rules can be determined from the reported experiments, and
risk assessment should be done on a case-by-case basis.
Given the limited information available, it is important that
dermatologists be aware of the use of encapsulation
technology in products that cause contact dermatitis as
encapsulation of product ingredients may affect allergeni-
city in some cases. Whether a product contains micro-
vesicles may be difficult to ascertain if it is not mentioned
on the label. Words such as ‘‘nanosphere,’’ ‘‘liposome,’’ and
‘‘encapsulated’’ can be looked for, but often these words
appear not on the label but rather in the marketing folder.
Based on information from the manufacturers or other
sources, the Web site ,www.nanotechproject.org. lists
consumer products that use nanotechnology and different
carrier technologies. The list is far from complete but can
be helpful. Dermatologists investigating patients with
allergic reactions to consumer products that use encap-
sulation technology should consider the risk of false-
negative results when testing with ingredients in conven-
tional patch-test vehicles. It is important to collaborate
with the manufacturer; manufacturers can sometimes
provide dermatologists with samples of encapsulated
compounds for patch testing.21 Whether these new
formulation systems really pose a risk for consumers in
regard to allergic skin reactions from the use of topical
products using this technology is not documented so far,
but experimental data show that such a risk is possible.
Dermatologists are urged to look for dermatitis patients
with possible allergic skin reactions from topical products
using nano- or microvesicle technology and to be aware
of the importance of patch-test vehicles.
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